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Every year in the United States, 2 million implant supported dental prostheses are placed in order 
to restore the functionality and cosmetic appearance of missing teeth. In over half of these cases, 
a bone grafting procedure must be performed to build the bony foundation necessary for implant 
survival. Unfortunately, the current gold-standard bone graft substitutes impart limited 
osteoconductivity and exhibit long degradation times leading to unpredictable outcomes. Thus, 
there exists a significant need for degradable dental bone graft substitutes capable of enhancing 
the bone regeneration process. 
The overall goal of this work was to design guided bone regeneration devices that address 
the limitations of current bone graft substitutes and barrier membranes. First, bone graft substitutes 
were synthesized from metallic magnesium (Mg) particles and poly-(lactic-co-glycolic acid) 
(PLGA) and subsequently characterized. These Mg/PLGA scaffolds were found to release 
magnesium at a controllable rate that ameliorated the acidic degradation profile of PLGA and 
enhanced bone marrow stromal cell proliferation in vitro. Next, we evaluated the Mg/PLGA 
scaffolds in a canine socket preservation model and found that the scaffolds increased bone height 
and bone volume regenerated relative to controls. 
 v 
Other groups have demonstrated enhanced osteogenic activity surrounding magnesium 
implants in orthopedic applications. However, the cellular mechanisms underlying these 
observations have not been well defined. Our next objective was to assess these cellular 
mechanisms in vitro, following exposure of bone marrow stromal cells (BMSCs) to varying 
concentrations of magnesium ion, simulating device degradation. We found that certain 
magnesium concentrations enhanced cell proliferation and matrix mineralization and impacted 
gene pathways associated with increased osteogenic activity. 
Finally, we designed and evaluated a Mg/PLGA barrier membrane and magnesium 
micromesh in a canine vertical ridge augmentation model which showed promise for a fully 
degradable and osteoconductive magnesium-based guided bone regeneration therapy. This work 
established the use of degradable magnesium devices for enhancing dental bone regeneration while 
expanding knowledge of the cellular mechanisms impacted by magnesium’s degradation.  
 vi 
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1.0  INTRODUCTION 
Every year in the United States, 2 million implant supported dental prostheses are placed in order 
to restore the functionality and cosmetic appearance of missing teeth (1). In over half of these 
cases, a bone grafting procedure must be performed to build the bony foundation necessary for 
implant survival. The current gold standards for treatment of these bone defects are autogenous 
and allogenic bone grafts, but there are size limitations and donor site morbidity for autogenous 
grafts, as well as prolonged recovery due to delayed osteoconductivity for allogenic grafts. In order 
to improve bone regeneration, degradable magnesium devices are currently being explored for 
enhanced fracture fixation and bone grafting materials. Mg devices implanted in vivo have been 
shown to be advantageous by exhibiting appropriate mechanical properties, minimizing 
inflammation and neighboring tissue damage and providing simultaneous promotion of osteoblast 
proliferation and biodegradation.  However, there remains a need for improved dental bone 
grafting therapies and for a better understanding of the biology underlying magnesium’s 
osteoconductive properties. 
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1.1 BONE LOSS AND CURRENT TREATMENTS 
1.1.1 Conditions and Injuries Leading to Dental and Craniomaxillofacial Bone Loss 
Many of the bones within the face suffer from fractures similar to those elsewhere in the body. 
The pediatric population is particularly susceptible to craniofacial bone fractures due to their 
greater cranial-mass-to-body ratio and account for up to 15% of all facial fractures (2). These 
injuries are often sustained in motor vehicle accidents, falls and sports-related accidents. In 
addition to bone fractures, dentoalveolar trauma represents a majority of craniofacial injuries 
reported in one study (3). Such trauma manifests itself in crown fracture and tooth subluxation or 
avulsion which can often result in the loss of one or more teeth. In the US, by age 65, the average 
person has lost 6 adult teeth due to trauma, disease or poor hygiene and 4% of the adult population 
has no remaining teeth (4). Significant bone loss can result following the loss of teeth as a result 
of reduced loading in the underlying bone. Significant bone loss can also occur in the craniofacial 
region as a result of blast injuries, tumor resections (5, 6) and radiotherapy (7). 
1.1.2 Current Bone Grafting Materials for Dental and Craniomaxillofacial Bone Loss 
Significant dental bone defects are caused by a wide range of events including open fractures, non-
unions, infection, tumor resection and radiotherapy.  These severe conditions can lead to a critical 
loss of bone, for which normal regeneration processes are inadequate at restoring adequate volume 
for maintaining dental implants. Unfortunately, current therapies for repairing these severe bone 
defects have limitations and drawbacks including high risk of complications, size constraints, poor 
quality of life during healing and poor function post-healing (8). Innovations in the development 
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of synthetic, porous, degradable scaffolds have shown promise in quickly, effectively and cost-
effectively regenerating bone compared to autografts, allografts and traditional synthetic bone 
graft substitutes. 
 
Table 1 Commercially available bone graft substitutes typically used for dental bone grafting 
procedures 
Product Name Manufacturer Composition 
Biogran Biomet3i Bioglass 
BioOss Geistlich Irradiated bovine bone +/- porcine 
collagen 
Easy-Graft Guidor/Sunstar PLGA + HA particles 
IngeniOs Zimmer Synthetic hydroxyapatite 
PerioGlas NovaBone Bioglass 
PRO-DENSE Wright Medical Calcium sulfate + calcium phosphate 
Puros Zimmer Demineralized human bone allograft 
RegenerOss Biomet3i Demineralized + mineralized human 
bone allograft 
Vitoss Stryker Bioglass 
Infuse Medtronic/BioHorizons Bovine collagen + rhBMP-2 
OP-1 Stryker Bovine collagen + rhBMP-7 
 
1.1.2.1 Autografts 
The current gold-standard treatment for regeneration of large bone defects is the autogenous bone 
graft. This treatment involves the harvest of “donor” bone tissue from other anatomical sites in the 
patient. Autografts are osteoinductive due to the presence of bioactive proteins and cells found in 
the healthy harvested bone (9). This osteoinductivity results in faster healing times and improved 
outcomes compared to other therapies for large bone defect repair (10). Since the “donor” tissue 
is harvested from the same patient there is also no risk of disease transmission or graft rejection. 
The biggest limitation of autogenous bone grafting is the availability of “donor” bone and the 
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morbidity associated with the harvesting procedure (8, 9, 11). Due to this limitation and the similar 
success rates of bone graft substitutes, allografts are not typically used for minor dental implant-
associated bone grafting (12, 13). However, for more complex dental bone grafting, a 
combinatorial grafting approach may be pursued which involves the use of bone graft substitutes 
combined with autogenic bone or bone marrow aspirates (14). 
1.1.2.2 Allografts 
Allogenic bone grafts address the size restrictions and donor site morbidity drawbacks of autogenic 
bone grafting. Allogenic bone is obtained from human cadavers by tissue banks and then screened 
for diseases, processed and resold to healthcare providers. Allogenic bone processing involves 
removal of cells and other antigenic components of the bone, typically through physical and 
chemical methods and gamma irradiation. The most common form of allogenic bone is 
demineralized bone which can be purchased in powder, particle, putty or block formulations (9, 
10). While allografts overcome the size limitation and donor site morbidity drawbacks of 
autografts, they suffer from decreased osteoconductivity due to the extensive processing and 
sterilization methods necessary to prepare the materials. Allografts also lack pre-vascularization 
and carry increased infection and graft rejection risks (8, 15). Since allografts come from various 
individual donors, there are also concerns with batch variability which can result in varied healing 
rates. In spite of these limitations, demineralized bone autografts are frequently used for dental 
bone grafting and result in generally good outcomes (12, 14). 
1.1.2.3 Synthetic, Growth Factor and Tissue Engineering Approaches 
There are a large number of reports in the literature on the use of porous scaffolds for bone tissue 
engineering, focusing primarily on polymers and ceramics. Many groups have developed porous 
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scaffolds that are functionalized with growth factors, such as commercially available recombinant 
human bone morphogenetic protein-2 (rhBMP2) and -7 (rhBMP7) doped collagen scaffolds (16). 
However, these products are expensive, have limited approved indications for use, require fixation 
with permanent materials and are associated with serious complications (17, 18). Therapies using 
magnesium would be less expensive and complex to manufacture, require less rigorous regulatory 
review, result in fewer complications and be fully degradable while capturing the same market 
segment. 
1.1.2.4 Barrier Membranes are used to Constrain and Protect Bone Grafts 
The aforementioned bone grafting materials are frequently used with barrier membranes as part of 
a guided bone regeneration “GBR” approach (Table 2). These barrier membranes are composed 
of processed biological or synthetic occlusive sheets that serve to constrain the bone graft material 
within the regenerating defect and prevent the ingrowth of gingival tissue (19). These barrier 
membranes can also be used without bone graft substitutes to protect regenerating bone defects 
from gingival tissue ingrowth as is commonly the case in periodontal applications (20, 21).  
 
Table 2 Commercially available barrier membranes typically used for guided bone regeneration. 
Product Name Manufacturer Composition 
Alloderm BioHorizons Decellularized human dermal matrix 
Guidor Guidor Sunstar Poly-lactic acid 
Inion Inion/Curasan PLGA 
Bio-Gide Geistlich Collagen 
conFORM/RCM6 ACE Surgical Collagen 
CopiOs Zimmer/RTI Biologics Bovine pericardium 
OsseoGuard Biomet3i Bovine dermal collagen 
Barrier membranes can be classified into three groups with distinct applications, 
advantages and disadvantages. Non-degradable barrier membranes, typically comprised of 
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expanded poly(tetrafluoroethylene) (ePTFE) are frequently used to protect and maintain slow-to-
heal bone defects (22, 23). While they exhibit good biocompatibility, they lack structural 
reinforcement needed to protect large defects and typically require surgical device removal 
following bone healing. Thus, titanium alloy reinforced ePTFE were developed to provide a larger 
degree of mechanical integrity (24, 25). Unfortunately, Ti-reinforced ePTFE membranes also 
require device removal surgeries and exhibit a high rate of membrane re-exposure due to the 
presence of rigid metal reinforcements. Finally, degradable barrier membranes are available that 
eliminate the need for device removal surgery following bone healing and significantly reduce the 
risk of re-exposure (26-28). These degradable membranes can either be natural (26) or synthetic 
(28, 29) in nature which allows for a wide range of mechanical/handling and degradation 
properties. Much of the current research on barrier membranes is focused on cell/material (30), 
growth factor/material (31, 32) and composite membranes (33-36) to overcome limitations of 
commercially available devices. 
Unfortunately, these degradable membranes do not possess the structural rigidity necessary for 
maintaining large bone grafting sites. Thus there remains a need for a mechanically reinforced, yet 
degradable barrier membrane. 
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Figure 1 Schematic of guided bone regeneration approach in a periodontal setting using a bone graft 
material and barrier membrane in an attempt to regenerate a bone defect. Republished from Chen, et. al. (37).  
1.1.3 Additional Significant Need for Bone Repair in Orthopedic and Spinal Applications 
Musculoskeletal injuries are the most common form of injuries and bone injuries and disorders 
make up a significant portion of these (38). Over 6.2 million bone fractures occur in the United 
States each year, 10 million Americans suffer from osteoporosis and 300,000 patients require bone 
grafting prior to receiving dental implants (39, 40). Treatments of bone injuries and disorders 
include medication to prevent or treat osteoporosis, conservative casting of long bone fractures, 
internal fixation of open fractures and elective bone grafting in preparation for dental implants. 
The burden of these treatments range from outpatient procedures with several hundred dollars in 
costs to long hospitalizations generating over $25,000 in medical costs (41, 42). Additional 
burdens are borne by the patients who face pain, limited mobility, as well as potential economic 
loss due to short and long-term disability. The significant incidence of bone injuries and cost of 
their subsequent treatments suggest that improving bone repair therapies could result in reduced 
healthcare costs. 
The 6.2 million bone fractures that occur in the United States each year result in an annual 
medical-cost of over $20 billion (8, 42).  The average person has a 29% chance of sustaining a 
fracture throughout the course of their life with fracture incidence rapidly increasing after 60 years 
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of age (43). Meling, et al, found that of all fractures requiring in-hospital treatment, 56% of 
fractures required some form of internal fixation (43), usually with titanium or stainless steel plates 
and screws (43). These permanent fixation devices frequently remain in the body which can result 
in local inflammation and metal sensitivities as the device surface wears and the surrounding bone 
may weaken due to stress shielding (44-46). In pediatric cases or with certain fracture locations, 
these devices are removed following healing. One study examining ankle fractures found that 72% 
of patients receiving permanent metallic fixation devices underwent a second removal surgery 
which increased total treatment cost by an adjusted US$2,400 or 27% compared to degradable 
fixation devices (47). Neither the removal of these fracture fixation devices nor their remaining in 
the body following bone healing are particularly desirable outcomes (48), thus new degradable 
materials have been developed to overcome these drawbacks. 
1.2 MAGNESIUM SHOWS PROMISE FOR BONE REPAIR DEVICES 
1.2.1 Magnesium Devices’ Degradation known to be Biocompatible 
Magnesium alloys were first used for biomedical applications over 200 years ago (49, 50); 
however, their widespread development for orthopedic applications did not accelerate until the 
manufacturing advancements were made in more recent decades (51-57). Magnesium alloys 
degrade through surface oxidation in aqueous environments, such as in the body (Eq 1. and 2.) 
(58). The Mg degradation products are absorbed into the blood and removed by the kidneys. 
Numerous studies have found that varying alloy synthesis parameters affects degradation rate and 
osteoconductivity in vivo (53, 54, 56, 57, 59-61). While Mg alloys have been found to be 
 9 
osteoconductive, few studies have examined the development of porous Mg scaffolds for large 
bone defect regeneration. 
          𝑀𝑀𝑀𝑀(𝑠𝑠) + 2𝐻𝐻2𝑂𝑂 →  𝑀𝑀𝑀𝑀(𝑂𝑂𝐻𝐻)2(𝑠𝑠) + 𝐻𝐻2                    (1) 
    𝑀𝑀𝑀𝑀(𝑂𝑂𝐻𝐻)2(𝑠𝑠) + 2𝐶𝐶𝐶𝐶− →𝑀𝑀𝑀𝑀𝐶𝐶𝐶𝐶2(𝑎𝑎𝑎𝑎) + 2𝑂𝑂𝐻𝐻−                (2) 
1.2.2 A Wide Range of Magnesium Devices have been Manufactured and Evaluated 
Magnesium alloys have been used for biomedical applications shortly after the discovery of 
elemental magnesium and the ability to manufacture it over 200 years ago (50). One of the first 
documentations of human use was reported in 1872 when Mg wires were used as degradable 
ligatures to control bleeding (49). Mg was explored for use in orthopedic applications due to its 
similar density and mechanical properties compared to bone (62). Reports on the use of Mg plates 
and screws for orthopedic reconstruction followed in 1906. Although clinical outcomes were 
promising, the difficulties of controlling degradation rate and assessing materials prior to human 
use limited their development (63). Numerous studies were conducted to determine the in vitro 
and in vivo responses of various alloys for various applications. However, difficulty characterizing 
cytotoxicity and osteogenicity in vitro meant future assessments of Mg scaffolds would rely 
primarily on expensive in vivo characterization techniques. 
1.2.3 Magnesium Based Scaffolds 
A wide variety of magnesium scaffolds have been synthesized and characterized. The bulk 
material for magnesium scaffolds can be synthesized using casting, selective laser sintering and 
other techniques (64). A basic design change that has been evaluated is the introduction of one or 
more alloying elements to the bulk Mg. Gu, et al. synthesized nine binary Mg alloys which were 
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subsequently found to affect mechanical and degradation properties, as well as cytotoxicity (51). 
After synthesis of the bulk material, numerous processing steps, such as annealing, extruding and 
surface treatments can be performed to further alter the behavior of the magnesium scaffold. These 
final processing steps can also include manufacturing of the final scaffold shape, including the 
introduction of pores to allow cellular infiltration (65). Testing each of these possible design 
iterations in vivo would be cost prohibitive and would lack in vitro biocompatability data required 
for regulatory approval. 
It has long been understood that porous biomaterials enable faster cell infiltration and tissue 
regeneration than their non-porous counterparts. The literature suggests that pore sizes  greater 
than 100um and higher overall porosity best support osteogenesis in vivo. (66). While there has 
been much work reported on porous polymer, hydroxyapatite and natural material orthopedic 
scaffolds, there are few reports of porous magnesium scaffolds in the literature. Several groups 
have created porous magnesium scaffolds using pressing, sintering and salt-casting techniques (65, 
67-69). These scaffolds exhibited good mechanical properties and porosity, but this synthesis 
method prevents more complex geometries from being constructed without advanced machining. 
Cifuentes, et. al., pressed and sintered PLLA/Mg sheets to create non-porous Mg/polymer 
scaffolds (70). A porous composite Mg powder/polymer scaffold could be synthesized using 
traditional casting and salt leaching techniques. Creation of these composite scaffolds would 
harness the osteoconductive properties of Mg, while overcoming limitations of currently available 
technologies. 
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1.2.4 Magnesium Device Evaluation is Limited in vitro 
The healthy human body is capable of removing very high concentrations of Mg and many 
common alloying elements. Previous in vitro examinations of cell viability and proliferation have 
used conditioned media with alloy degradation products which is not physiologically relevant and 
fails to take into account temporal aspects of degradation (51, 56, 57). Li, et al allowed cells to 
attach and proliferate prior to placing a Mg alloy onto the cells (52, 71). This method also does not 
model the in vivo regeneration process where cells would be required to attach and proliferate on 
a Mg scaffold. Two groups performed cytotoxicity evaluations by seeding cells directly onto 
magnesium alloys (71, 72). While this model is the most physiologically relevant, this and other 
proliferation assays performed were rudimentary and destructive, such as cell counting (52, 73) 
and MTT (51, 53, 56, 57, 72, 74) assays. Recently, several traditional proliferation assays 
functioning on metabolic cycles, such as MTT were found to be confounded by Mg (75). 
Limitations of the studies aside, most have found that bone-related cell lines tolerate magnesium 
and most of its alloying elements well and that for several alloys, cell proliferation was increased. 
However, the in vitro assessments of cytotoxicity reported in the literature are not physiologically 
relevant, time consuming and sample-destructive. 
1.2.5 Magnesium Scaffolds’ Performance in vivo 
Numerous studies have examined the biocompatibility and osteogenicity of Mg scaffolds in vivo. 
Mg scaffolds of varying composition (56, 57, 59-61), porosity (53) and surface treatments (54) 
have been implanted in animals to assess their osteogenicity in bone defects. These studies have 
all found that varying Mg scaffold properties affects degradation rate and cellular invasion. 
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However, all studies have found Mg scaffolds are osteoconductive and allow full regeneration of 
bone in the defect using histological stains (53, 54, 59, 61) and radiographic methods (54, 61) 
(Figure 2). Although in vivo characterizations of Mg scaffolds for bone regeneration have yielded 
promising results, a lack of comprehensive in vitro assessments present significant regulatory 
hurdles in the development of subsequent medical devices. Additionally, iterative design changes, 
such as varying alloying element concentrations or scaffold processing steps would require 
additional in vivo studies to requalify toxicity and osteogenicity properties. 
 
Figure 2 Figure republished from Chaya, et al (76). Significant bone formation was identified 
surrounding implanted magnesium devices and significant bone/device contact was identified which showed 
promise for magnesium bone devices. A longitudinal slice of a Mg plate (P) and screw (S) shows areas of bone 
contact around the screw head, shaft, and plate edge (A). A transverse slice of a Mg screw shaft (S) shows bone 
contact around the screw perimeter after 16 weeks (B). Toluidine Blue shows bone morphology at bone-plate 
(P) interface after 8 weeks (C). 
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1.2.6 Little Understanding of Magnesium’s Inflammatory, Angiogenic and Osteogenic 
Capabilities 
Solubilized magnesium ion (Mg2+) is known to be a co-factor for many enzymes, as well as a 
stabilizer of DNA (77). Since, Mg2+ is an important component of the human physiology, it is 
important to determine the local effect of the resorbed alloys on the cells. Several reports have 
suggested stimulatory effects on the growth of new bone tissue (74, 78). However, few 
investigations have identified specific Mg2+ effectors relevant to osteogenesis or predictive of Mg 
alloys’ performances in vivo. Mg2+ has been found to increase expression of vascular endothelial 
growth factor, proliferation and migration in human umbilical vein endothelial cells suggesting 
that magnesium could support angiogenesis which may be a source of the enhanced osteogenesis 
observed in vivo (79, 80). Examining angiogenic and inflammatory markers in tissue surrounding 
magnesium implants could elucidate the mechanisms that underlie the enhanced bone regeneration 
seen in vivo. 
The healthy human body is capable of removing very high concentrations of Mg and many 
common alloying elements. Previous in vitro examinations of cell viability and proliferation have 
used conditioned media with alloy degradation products which is not physiologically relevant and 
fails to take into account temporal aspects of degradation (51, 56, 57). Li, et al allowed cells to 
attach and proliferate prior to placing a Mg alloy onto the cells (52, 71). This method also does not 
model the in vivo regeneration process where cells would be required to attach and proliferate on 
a Mg scaffold. Two groups performed cytotoxicity evaluations by seeding cells directly onto 
magnesium alloys (71, 72). While this model is the most physiologically relevant, this and other 
proliferation assays performed were rudimentary and destructive, such as cell counting (52, 73) 
and MTT (51, 53, 56, 57, 72, 74) assays. Recently, several traditional proliferation assays 
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functioning on metabolic cycles, such as MTT were found to be confounded by Mg (75). 
Limitations of the studies aside, most have found that bone-related cell lines tolerate magnesium 
and most of its alloying elements well and that for several alloys, cell proliferation was increased. 
However, the in vitro assessments of cytotoxicity reported in the literature are not physiologically 
relevant, time consuming and sample-destructive. 
Magnesium scaffolds for bone regeneration are required to recruit mesenchymal stem cells 
and support osteogenic differentiation. Most osteogenic gene profiling performed in vitro has used 
quantitative polymerase chain reaction (qPCR) for quantification of specific gene expression 
following experimental manipulation. In experiments analyzing the osteogenic capacity of Mg 
scaffolds, matrix production and remodelling was observed to be increased through Col-I, II and 
IX and MMP-13 expression (73). Additionally, Mg scaffolds were found to increase expression of 
alkaline phosphatase (71, 74), an established marker of bone formation. Several of the studies 
examining in vitro cytotoxicity assess basic osteogenic markers, such as alkaline phosphatase 
secretion (53, 71, 74) or mineralization through von Kossa staining (74). These studies use 
rudimentary and destructive assessment techniques that are not conducive to rapid and 
comprehensive screening of candidate alloys. 
1.3 DEGRADABLE POLYMERS 
1.3.1 Degradable Polymers used for Medical Applications 
Polymers can be found naturally, many inside the body, or synthesized synthetically and have 
various chemical, mechanical and degradation properties. Degradable polymers have been used 
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for a wide range of medical applications, such as drug delivery vehicles, sutures, bone graft 
substitutes, barrier membranes wound healing bandages and skin grafts, bone cement plugs, suture 
anchors, hernia repair meshes, clips, pins and fracture fixation plates and screws (81-84) (Table 
3). These degradable polymers are frequently classified by their mechanism of degradation. 
Degradation typically occurs hydrolytically (i.e. the body’s hydrate environment cleaves bonds 
within the polymer) or enzymatically (i.e. enzymes within the body, such as proteases, cleave 
bonds within the polymer). Hydrolytically degradable polymers are comprised of many synthetic 
polymer classes of interest for biomedical applications including PLA, PGA, and PCL. These 
polymers are often co-polymerized to yield PLGA or PLA-PCL blends to tailor polymer product 
degradation time for varying applications. Enzymatically degradable polymers are comprised of 
many natural polymer classes used for medical products. Collagen, fibrin, elastin, chitosan, 
hyaluronic acid and other biologically occurring polymers are frequently harvested from allogenic 
or xenogenic sources and processed to form gels, sheets and scaffolds for a range of biomedical 
applications (27, 85, 86). Finally, many combination polymer products exist as a means to leverage 
multiple polymers’ characteristics, such as PEG-PLA(87). All of these polymers tend to be 




Table 3 Commercially available polymer devices relevant to bone regeneration and repair procedures 
Product 
Name 
Application Manufacturer Composition 
Dexon Suture Covidien PGA 
Vicryl Suture Ethicon PLGA 
Monacryl Suture Ethicon PCL 
Lactosorb Fracture fixation 
system 
Biomet PLGA 
Rapidsorb Fracture fixation 
system 







Depuy Synthes PLLA + B-TCP 
 
1.3.2 Degradable PLGA-Based Bone Repair Devices 
PLLA, PLDLA and PLGA have been extensively studied in bone repair applications and have 
been used to synthesize commercially available and FDA-approved fracture fixation devices (88). 
These devices are generally associated with good outcomes, but have been associated with the 
development of sterile abscesses (82, 89, 90). Researchers hypothesize that the development of 
these abscesses may be due to a non-specific foreign body reaction in response to the acidic 
degradation profile these polymers exhibit. This hypothesis is further supported by in vitro 
cytocompatibility assessments of PLDLA and PLGA extracts which showed that high 
concentrations of degradation products decreased cell proliferation and viability (91). Animal 
studies carried out with commercially available LactoSorb PLGA plates and screws have more 
intensively studied the temporal biological response to device degradation. Eppley, et. al., found 
that fibrous tissues typically encapsulate the devices at 2 months while an increased macrophage 
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and fibrovascular presence is observed 6 months post-implant. As the device continues to degrade 
through one year, the macrophage presence decreases, as there are fewer remaining degradation 
products, and few inflammatory cells remain (92). 
1.3.3 Polymer-Based Composites 
Numerous studies have examined polymer/mineral and polymer/ceramic composite scaffolds (93-
98). One study examined polymer coating of a bulk Mg alloy (99) and another studied Mg/TCP-
doped collagen scaffolds (100). Hydroxyapatite (HA)/PLLA composite scaffolds have also 
received great attention with several HA/PLLA screws commercially available for clinical use 
(101, 102). Cifuentes, et. al., examined embedding magnesium within a PLLA matrix, but did not 
assess in vivo biocompatibility (70). There are no reports of porous Mg/polymer scaffolds, barrier 
membranes or meshes for bone tissue engineering. Coupling Mg powder with polymers could 
allow rapid prototyping of complex patient/injury-specific scaffolds for bone regeneration, as has 
been accomplished with hydroxyapatite powder and polymeric binders (103). Additionally, there 
is a much larger body of literature regarding functionalization of polymers with growth factors, 
and drugs than there is for Mg (81, 104). A drawback of some polymers is that their acidic 
byproducts that can threaten cell attachment and viability, as well as protein delivery (105). 
Addition of Mg, which produces hydroxide ions during its corrosion (Eq. 2), to these polymers 
could create a buffering effect to eliminate the drawbacks of acidic polymer products. Finally, 
polymers are less commonly used for bone healing applications due to their low strength compared 
to bone and traditional orthopedic metals, such as titanium and stainless steel. Doping polymer 
scaffolds with Mg could increase their mechanical strength and increase their utility for bone 
healing applications (70). Composite materials containing both Mg-based powder and polymer 
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could serve as a whole platform for therapeutics capturing the advantages of both Mg alloy and 
polymer systems. 
1.4 OVERALL RESEARCH GOAL AND SPECIFIC AIMS 
The incidence of dental bone grafting procedures and the cost associated with them has made 
dental bone tissue engineering an attractive field of study. New technologies and therapies are 
needed to provide low-cost, less-painful and more reliable bone void regeneration. The clinical 
goal of this research is to develop guided bone regeneration materials capable of providing faster 
bone regeneration in a fully degradable manner through the combination of magnesium and PLGA. 
Additionally, through this research we will expand our knowledge on the biological effects of 
magnesium, specifically in terms of osteogenesis, angiogenesis and inflammatory processes. Our 
research group hypothesized that successful creation and characterization of a magnesium-based 
bone grafting platform would demonstrate enhanced osteogenicity both in vitro and in vivo 
compared to clinically used gold-standard materials. 
1.4.1 Specific Aim 1: Synthesize and Perform Material Characterizations of 
Magnesium/PLGA Composite Scaffolds 
Scaffolds with varying Mg/NaCl ratios will be fabricated using PLGA/DCM solvent casting with 
negative salt casting technique. Scanning electron microscopy, true and apparent density and 
mercury intrusion porosity techniques will be used to determine scaffold porosity. Degradation 
analyses will be performed through pH measurement and inductively coupled plasma atomic 
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emission spectroscopy measurement of released magnesium. Mechanical properties will be 
measured with compression testing. Indirect cytocompatibility assessment will be performed 
based on ISO-10993 with bone marrow stromal cells and an MTT assay. The outcomes of these 
assays were analyzed to select an optimized Mg/PLGA composition for further study in Specific 
Aim 2. 
We hypothesized that porous Mg/PLGA scaffolds could be successfully manufactured 
using a solvent casting salt leaching method. Additionally, we hypothesized that the incorporation 
of metallic magnesium particles into a PLGA scaffold would 1) increase compressive strength and 
modulus, 2) buffer the acidic byproducts of PLGA degradation, 3) release magnesium throughout 
degradation and 4) enhance bone marrow stromal cell proliferation compared to PLGA Only 
scaffolds. 
1.4.2 Specific Aim 2: Evaluate the Therapeutic Potential of Magnesium/PLGA Scaffolds 
in a Canine Socket Preservation Model 
Mg/PLGA scaffolds will be used as a bone grafting material and implanted into canine pre-molar 
sockets following tooth extraction. Following 8wk and 16wk healing periods, mandibles will be 
explanted, formalin fixed and subjected to microCT analysis in order to quantify bone regeneration 
and assess scaffold degradation. Following micro-CT, samples will be trimmed, embedded in 
plastic and sectioned in preparation for histological analysis. Goldner’s Trichrome staining will be 
used to examine general tissue morphology. Alizarin Red and von Kossa staining will be used to 
identify mineralized tissue within the healing tooth sockets. Chloroacetate esterase staining will 
be performed in order to identify any neutrophil collections indicative of inflammation in the 
healing site. 
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We hypothesized that the Mg/PLGA scaffolds could be successfully implanted into the 
socket defects and proven safe and effective at regenerating bone in a canine socket preservation 
model. We also hypothesized that the bone height and bone volume of the Mg/PLGA treated 
defects would be increased compared to defects left empty. 
1.4.3 Specific Aim 3: Evaluate the Osteogenic, Angiogenic and Inflammatory Gene 
Expression Profile of hBMSCs exposed to Magnesium 
Human bone marrow stromal cells will be cultured in vitro and exposed to varying concentrations 
of magnesium sulfate (MgSO4) as a standardized simulation of degrading magnesium implants. 
The hBMSCs will be maintained in standard maintenance medium or exposed to osteogenic 
differentiation medium in addition to the MgSO4 supplementation. hBMSC proliferation will be 
determined using trypan blue exclusion and counting with a hemocytomer, as well as the MTT 
assay at 1, 3, 5 and 7 days post-plating. Matrix mineralization will be assessed using Alizarin Red 
staining followed by dye solubilization and quantification following 3 weeks of culture. Also at 
the 3 week experimental endpoint, RNA and total protein will be extracted from the cell 
monoloayers and subjected to qPCR and Western blotting, respectively. The findings from qPCR 
will be input to gene network analysis software to identify proteins of interest for further 
investigation of Mg-affected pathways. 
We hypothesized that increased concentrations of magnesium in cell culture medium 
would result in increased cell proliferation and matrix mineralization. Additionally, we aimed to 
identify possible Mg-affected pathways that could explain the increased bone regeneration 
observed around Mg implants in vivo. 
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1.4.4 Specific Aim 4: Synthesize and Perform a Proof-of-Concept in vivo Implantation of 
a Complete Magnesium-Based Guided Bone Regeneration Platform 
Mg/PLGA guided bone regeneration barrier membranes will be synthesized using a solvent-
casting approach. Additionally, a magnesium micromesh will be fabricated using a laser-cutting 
approach. These devices will be implanted in a canine vertical ridge augmentation model using 
magnesium screws as a grafting material. Following explantation at 12wks post-implantation, 
explants will be subjected to microCT scanning, formalin fixed and embedded in plastic. Bone 
height and bone volume regenerated will be calculated using microCT scan analysis. Following 
plastic embedding, histological analysis will be performed to assess general biocompatibility, 
osteogenic and inflammatory response. 
We hypothesized that a magnesium/PLGA barrier membrane and magnesium micromesh 
could be synthesized meeting the design criteria of currently used barrier membranes. 
Additionally, we hypothesized that the barrier membrane, micromesh and magnesium screw could 
be successfully implanted in our in vivo model with no adverse events. We compared the 
performance of our magnesium-based guided bone regeneration platform to a repair with a 
commercially available bone graft substitute secured by titanium micromesh. 
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2.0  SPECIFIC AIM 1: SYNTHESIS AND MATERIAL CHARACTERIZATION OF 
MAGNESIUM/PLGA SCAFFOLDS 
Figure 3 Experimental overview of Specific Aim 1 
 
The first step in achieving the overall research goal of this thesis was to synthesize, optimize and 
characterize the material properties of the magnesium/PLGA scaffolds (Figure 3). During the 
preliminary phases of this study, several different polymer components including fibrin, 
PEG/gelatin, alginate, polycaprolactone (PCL), chitosan and three variations of PLGA were 
considered based on their manufacturability and adherence to design criteria in Table 4. 502H 
PLGA was identified as the most promising polymer component due to its widespread clinical use 
in other devices, mechanical strength, tunable degradation properties and versatility. The synthesis 
and characterization of these magnesium/PLGA scaffolds was described in: Brown A, Zaky S, 
Ray H, Sfeir C. Porous magnesium/PLGA composite scaffolds for enhanced bone regeneration 
following tooth extraction. Acta Biomaterialia 11(1): 543-53, 2015. Portions of the manuscript are 
reproduced here with permission of the publisher.  
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Table 4 Design criteria guiding evaluation of magnesium/polymer scaffolds 
 
2.1 INTRODUCTION 
Magnesium and magnesium alloys have been increasingly researched in the past decade 
and have been found to be excellent biomaterials for orthopedic applications (58). Magnesium 
degrades non-toxically in the body, thus allowing full bone regeneration in the implant site (106). 
Magnesium has also been shown to increase osteoconductivity in vivo compared to polymer rods 
(59). Furthermore, in vitro studies found that exposing cells to magnesium increased proliferation 
and expression of osteogenic markers (73, 107). Overall, magnesium provides many of the 
osteoinductive effects seen with recombinant growth factors while remaining significantly less 
expensive and safer. 
Composites have been widely used for bone regeneration scaffolds and fixation devices 
including organic/inorganic composites such as collagen/HA (97) and polymer/mineral 
composites such as PLGA/B-TCP and PLLA/HA (98). However, little work has focused on 
composites of polymers and metallic magnesium particles. Magnesium salts, such as MgCO3 and 
 
Cell Attachment Support BMSC Attachment 
Cell 
Proliferation Increase BMSC Proliferation 
Degradation 
Time 8-12 weeks 
Mg Release Throughout full degradation time 
Compressive 
Modulus > 50MPa 
Compressive 
Yield Strength > 2MPa 
Pore Size > 100um 
 24 
Mg(OH)2, have been embedded in PLGA microspheres and scaffolds and were found to buffer the 
acidic pH degradation of the PLGA (108, 109). This was found to increase bioavailability of 
proteins and drugs encapsulated in the PLGA/Mg microspheres. Other studies have investigated 
coating bulk magnesium alloys with PLGA, PLLA or PCL in order to control the degradation rate 
of the alloy (99, 110, 111). These coatings were found to decrease short-term degradation rate, as 
well as increase cell attachment and viability on the coated-alloy. Cifuentes, et. al., produced non-
porous PLLA/Mg cylinders through compression of numerous solvent-casted thin films (70). This 
process found that inclusion of Mg particles into the PLLA matrix enhanced mechanical strength 
of the scaffolds. While these studies captured various advantages of combining polymers and 
several forms of magnesium, none synthesized porous magnesium/PLGA composites for use as 
bone tissue engineering scaffolds. 
The overall goal of this study was to develop and characterize a porous metallic magnesium 
particle/PLGA scaffold in order to harness the advantages and strengths of both polymers and 
magnesium. In order to investigate the impact of varying amounts of magnesium on scaffold 
mechanical, degradation and cytocompatibility properties, we explored a range of Mg/NaCl 
compositions in PLGA. We hypothesized that the addition of metallic magnesium particles into 
the PLGA scaffold would 1) increase compressive strength and modulus, 2) buffer the acidic 
byproducts of PLGA degradation, 3) release magnesium throughout its degradation and 4) enhance 
bone marrow stromal cell proliferation. 
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2.2 MATERIALS AND METHODS 
2.2.1 Synthesis of Scaffolds 
Four compositions of magnesium/PLGA scaffolds were synthesized using a traditional solvent 
casting, salt leaching technique (112) (Figure 4). The scaffold compositions were chosen such that 
the mass of PLGA was constant between the four groups while the magnesium mass was varied. 
In order to produce scaffolds of the same size, variations in the mass of Mg particles was balanced 
by the addition of sodium chloride particles. First, molds were created by covering one open end 
of Tygon tubing pieces with aluminum foil (Cole Parmer, Vernon Hills, IL) to produce cylindrical 
scaffolds in small (3mm Diameter, 8mm Length), medium (7mm D, 6mm L) and large (6mm D, 
8mm L) sizes. These geometries were chosen in order to provide the optimal sample dimensions 
for downstream characterizations discussed below. Next, the molds were filled with pure metallic 
magnesium particles (>99% purity, <300um particle size, Sigma Aldrich, St. Louis, MO), sodium 
chloride (Sigma Aldrich), sieved to a particle size of 106um-212um, or a mixture of Mg particles 
and NaCl according to Table 5 for small scaffolds. Medium scaffold molds were filled in the same 
manner with twice the masses listed in Table 5 while large scaffolds were filled with four times 
the masses listed in Table 5.  
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Table 5 Compositions for small Mg/PLGA scaffolds. Medium scaffolds were synthesized with 2x the 
masses and large scaffolds with 4x the masses described in the table. 
 
Once the molds were filled with Mg and/or NaCl, PLGA (50:50, Mw 7,000-17,000, Sigma 
Aldrich) was dissolved into dichloromethane (DCM, Sigma Aldrich) at a concentration of 40% 
(w/v) and briefly sonicated. Volumes of 100ul, 200ul or 400ul of the PLGA/DCM mixture were 
then pipetted into the small, medium and large molds, respectively. The molds were left in a fume 
hood for 48h to allow DCM evaporation after which the scaffolds were removed from the molds 
and allowed to vent for an additional 24h. 
Salt leaching was performed by placing scaffolds in ddH2O at a ratio of 5ml/scaffold, 
10ml/scaffold and 20ml/scaffold for small, medium and large scaffolds, respectively. The 
scaffolds in ddH2O were placed on an orbital shaker and the ddH2O was replaced three times over 
the course of 24h. Immediately before and after each ddH2O change, the scaffolds were vacuumed 
to -60kPa for 5min to encourage water flow into the scaffolds. After salt leaching was complete, 
scaffolds were placed in the fume hood to dry for 48h. All scaffolds were weighed before and after 
salt leaching to confirm full salt washout. 
Following salt washout and drying, scaffolds were lyophilized for 48h. Scaffolds for all 
assays were then placed into sealed tubes and gamma sterilized with a dose of 20,000Gy at a dose 
 Mg Mass (mg) NaCl Mass (mg) PLGA Mass (mg) 
PLGA + 40mg Mg 40 0 40 
PLGA + 20mg Mg 20 40 40 
PLGA + 10mg Mg 10 60 40 
PLGA Only 0 80 40 
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rate of 23.5Gy/min (Mark I 68, JL Shepherd and Associates, San Fernando, CA) prior to use in 
the characterizations described below. 
 
Figure 4 Synthesis Overview of Mg/Polymer Scaffolds. A) 50%/50% Mg / NaCl mixture B) Mg/NaCl 
mixture in tygon tubing mold C) Scaffold with NaCl after polymerization of PLGA in DCM D) High 
magnification view of Mg/PLGA scaffold prior to salt washout E) Final Mg/PLGA scaffold after NaCl washout. 
 
2.2.2 Compression Testing 
Six medium scaffolds per group were subjected to unconfined compression testing using a 
materials testing machine (Instron Model #5566, Norwood, MA) outfitted with a 2000N load cell. 
A 0.2N preload was applied to the sample followed by compression at a crosshead displacement 
of 0.2mm/min until sample failure or 0.30 strain was reached. Stress and strain were calculated by 
dividing the load and elongation data by pre-compression cross-sectional area and height, 
respectively. Maximum stress was defined as the point at which the material exhibited a failure 
resulting in a decrease in load of greater than 50%, or in the case of failure by barreling, the load 
at 30% strain. Modulus was defined by measuring the slope of the linear portion of the curve 
immediately prior to maximum load. 
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Two univariate one-way ANOVAs with Dunnett’s post-hocs were performed to assess 
differences in maximum stress and modulus between the Mg/PLGA and PLGA Only scaffolds 
(SPSS, IBM, Armonk, NY). 
2.2.3 Porosity Characterization 
The porosity of three large scaffolds per group was calculated through the measurement of true 
and envelope density for three scaffolds per group. The true density of each scaffold was measured 
using a gas displacement density analyzer (AccuPyc 1340, Micromeritics, Norcross, GA) with 5 
purge/measurement cycles at 19.5psig. The same scaffolds were then subjected to envelope density 
analysis (GeoPyc 1360, Micromeritics) with a consolidation force of 38N. Porosity was calculated 
by dividing apparent density by true density.  
The pore size distribution of one large sized scaffold per group was measured using 
mercury intrusion porosity (AutoPore IV, Micromeritics). Samples were subjected to mercury 
intrusion pressures from 0.5-30,000psia correlating to pore sizes of 346-0.005um. Pore size 
distribution and median pore size for each sample was analyzed. 
Scanning electron microscopy (SEM) was also performed to qualitatively examine scaffold 
porosity and morphology. Small sized scaffolds were briefly dipped in liquid nitrogen and then 
fractured to provide both an outer and cross-sectional surface for imaging. Scaffolds were sputter 
coated with gold/palladium to a thickness of 6nm (Cressington #108auto, Watford, England). After 
sputter coating, scaffolds were mounted in order to image three outer surfaces and three cross-
sectional surfaces per group (JEOL #JSM 6335F, Tokyo, Japan). 
A one-way ANOVA was performed to assess differences in porosity, as measured using 
true and apparent density, between the scaffold groups. 
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2.2.4 Degradation Testing 
Four small scaffolds per group were subjected to degradation testing in order to characterize 
changes in pH and Mg release over the course of 10 weeks. Following gamma sterilization, 
scaffolds were placed into 12 well tissue culture plates, immersed in 5ml BMSC growth medium 
(formulated as described below) and placed in a tissue culture incubator. Early timepoint media 
sampling was performed at 1h, 1d and 3d by extracting 500ul of medium from each sample and 
immediately replenishing it with 500ul of fresh medium. Following the early timepoints, the full 
5ml of medium was extracted and replaced on a weekly basis for a total of 10 weeks. 
Immediately upon sampling the medium, the pH was measured using a combination pH 
electrode (Hanna Instruments #1083B, Smithfield, RI) and pH meter (Beckman #350, 
Indianapolis, IN).  
Media samples were thawed and diluted 20X in HEPES-buffered saline and subjected to 
inductively coupled plasma atomic emission spectroscopy (Thermo Fisher #iCAP 7200, Waltham, 
MA) in order to determine concentration of magnesium in the medium. The average of 3 
measurements of the Mg2790 line were taken for each sample, multiplied by 20 to obtain undiluted 
concentration in parts per million then divided by magnesium’s molecular weight to obtain 
concentration in millimolar. 
Differences in media pH during the degradation assessment were analyzed using a one-
way ANOVA with Dunnett’s post-hocs at each timepoint. 
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2.2.5 Indirect Cytocompatibility 
BMSC growth medium was formulated according to Colter, et al, and Sekiya, et al (113, 114). 
Medium was sterile filtered following the combination of 82.5% alpha minimum essential medium 
with L-glutamine, without ribonucleosides, without deoxyribonucleosides (Life Technologies, 
Grand Island, NY), 16.5% fetal bovine serum (premium select, Atlanta Biologicals, Atlanta, GA), 
1% penicillin G (10,000 units/ml, Lonza, Basel, Switzerland) and streptomycin sulfate 
(10,000ug/ml) and 1% L-glutamine (200mM, Life Technologies). The pH of BMSC growth 
medium as-formulated was 7.5-7.6 at 37degC and 5% CO2. 
Cytocompatibility testing of the Mg/PLGA scaffolds was performed using an indirect 
method adapted from ISO 10993:5, 10993:12 and Fischer, et al (115). Extracts were obtained by 
immersing small scaffolds (10 per group) in BMSC growth medium at a ratio of 200mg scaffold / 
1000ul extraction medium and then allowing the scaffolds to degrade for 72h at 37degC on an 
orbital shaker. After 72h, the individual medium extracts from each group of scaffolds were pooled 
and 2X, 4X and 10X dilutions with fresh medium were created. 
Bone marrow stromal cells for the indirect cytocompatibility assay were obtained from the 
Institute for Regenerative Medicine at Scott & White and cultured based on Colter, et al, and 
Sekiya, et al (113, 114). A vial containing one million P1 BMSCs were plated in growth medium 
in a 10cm dish and allowed to recover overnight. BMSCs were passaged by re-plating at a density 
of 10,000 cells per T175 flask. This process was repeated twice such that P4 BMSCs were obtained 
for use in the indirect cytocompatibility assay. 
Bone marrow stromal cells were plated in 96 well plates at a density of 500 cells/well in 
100ul of BMSC growth medium. After the cells were allowed to attach and proliferate for 24h, the 
growth medium was aspirated and the scaffold extraction medium and extraction medium dilutions 
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were added (n=6 per extract). The cells were cultured for an additional six days with the extraction 
medium aspirated and replenished on day 3. 
A Vybrant MTT assay (Life Technologies #V13154) was performed according to 
manufacturer’s instructions on day 6 after aspirating the extraction medium and washing all wells 
with PBS. 100ul of the MTT reagent in phenol red-free alpha-MEM was added to each well of the 
96 well plate and incubated at 37degC for 4h. Then 100ul of SDS-HCl solution was mixed into 
each well and allowed to incubate at 37degC for an additional 14h. Finally, the absorbance of all 
wells at 570nm was read using a standard plate reader (Molecular Devices Spectramax 190, 
Sunnyvale, CA). The absorbances for the Mg/PLGA scaffold extract groups were each normalized 
to the absorbances for the PLGA Only scaffold extract groups.  
A one-way ANOVA with Dunnett’s post-hocs was performed on the MTT absorbance data 
to assess statistical differences in proliferation between the Mg/PLGA and PLGA Only scaffold 
groups. 
2.3 RESULTS 
2.3.1 Porous Magnesium-PLGA Composite Scaffolds were Successfully Synthesized 
The solvent casting salt leaching method for synthesizing Mg/PLGA scaffolds was found to be 
successful. Following the solvent casting step, the scaffolds weighed on average 10±6% less than 
expected based on masses in Table 5 suggesting that nearly the entirety of the Mg/NaCl was bound 
by nearly the entirety of PLGA added to each scaffold.  Following salt washout, the scaffolds were 
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found to weigh on average 1±8% less than expected based on Table 5 suggesting that all of the 
NaCl was removed using our salt washout protocol. 
Gross examination of the scaffolds was performed using a digital camera and stereo 
microscope both before and after salt-washout. As seen in Figure 5, the Mg/PLGA scaffolds 
exhibited both a larger length and diameter than the PLGA Only scaffolds after the completion of 
synthesis. Interestingly, the Mg/PLGA scaffolds exhibited roughly equal length and diameter 
compared to the PLGA Only scaffolds prior to salt washout. 
 
Figure 5 Mg/PLGA composite scaffolds were successfully synthesized. Stereo microscope images of 
representative samples for the four scaffold compositions after completion of solvent casting, salt leaching and 
lyophilization (Scale bar = 2mm for all images). 
 
2.3.2 PLGA + 40mg Magnesium Scaffolds Exhibited Increased Maximum Strength and 
Modulus compared to PLGA Only Scaffolds 
Six medium sized scaffolds per group underwent compressive failure until catastrophic cracking 
occurred or 0.30 strain was reached. The maximum stress reached by the PLGA + 40mg Mg 
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scaffolds (241±84kPa) was significantly higher (p<0.001) than the PLGA Only scaffolds 
(79±7kPa) (Figure 6A). There was no significant difference between PLGA + 20mg Mg (30±6kPa) 
or PLGA + 10mg Mg (26±6kPa) and PLGA Only scaffolds. PLGA + 40mg Mg scaffolds 
(2.9±0.7MPa) also exhibited a significant increase (p<0.001) in compressive modulus compared 
to PLGA Only scaffolds (0.7±0.1MPa) (Figure 6B). Again, PLGA + 20mg Mg (0.9±0.3MPa) and 
PLGA + 10mg Mg (0.7±0.2MPa) did not exhibit significant differences in compressive modulus 
compared to PLGA Only scaffolds. The Mg/PLGA scaffolds failed through cracking in all cases, 
while the PLGA Only scaffolds experienced barreling until 0.30 strain was reached. 
 
Figure 6 PLGA + 40mg Mg scaffolds exhibit increased maximum strength and modulus compared to 
PLGA only scaffolds. Mg/PLGA scaffolds were subjected to compressive testing in order to determine A) 
maximum stress and B) compressive modulus. The bars represent means + standard deviations (* p < 0.001, 
n=5, ANOVA with Dunnett’s post-hoc). 
 
2.3.3 Magnesium/PLGA Scaffolds are Highly Porous and Contain Macropores 
The porosities of the PLGA + 40mg Mg (55±5%), PLGA + 20mg Mg (69±6%) and PLGA + 10mg 
Mg (72±9%) scaffolds were not significantly different compared to the PLGA Only scaffolds 
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(69±15%) (Figure 7A). The true densities measured for the four scaffold groups ranged from 
1.4g/cc for the PLGA Only group to 1.6g/cc for the PLGA + 20mg Mg group (data not shown). 
The pore size distribution as measured with mercury intrusion porosity was found to be 
similar between the four scaffold groups with minor differences seen in the overall porosities 
(Figure 7B). Median pore sizes were 48um, 41um, 46um and 37um for the PLGA + 40mg Mg, 
PLGA + 20mg Mg, PLGA + 10mg Mg and PLGA Only scaffolds, respectively. All scaffolds 
exhibited a negligible pore volume derived from pore sizes less than 5um. Additionally, all 
scaffolds exhibited a large pore volume derived from pores greater than 50um, particularly the 
PLGA + 10mg Mg and PLGA + 20mg Mg groups. 
Scanning electron micrographs of the four scaffold groups provided qualitative data as to 
the porosity and pore size distribution. PLGA + 40mg Mg scaffolds were comprised of Mg 
particles densely glued together with PLGA resulting in pores as a result of particle packing 
limitations of the Mg particles (Figure 7C). PLGA + 20mg Mg and PLGA + 10mg Mg scaffolds 
exhibited similar morphologies to each other with more pores and larger pores derived from the 
empty space remaining from NaCl crystals that were washed out (Figure 7D-E). Additionally, The 
PLGA + 20mg Mg and PLGA + 10mg Mg scaffolds showed a more disrupted Mg matrix when 
compared to the PLGA + 40mg Mg scaffolds. Finally, the PLGA Only scaffolds exhibited a PLGA 
matrix with cubic pores derived from the washed out salt and a more densely packed appearance 
than the PLGA + 10mg Mg and PLGA + 20mg Mg scaffolds (Figure 7F). 
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Figure 7 Mg/PLGA scaffolds are highly porous and contain macropores suitable for cell infiltration. 
A) Mg/PLGA scaffolds subjected to mercury intrusion porosimetry contained a large proportion of pores > 
50um (n=1). B) Overall porosity of Mg/PLGA scaffolds were not significantly different from PLGA Only 
scaffolds as measured by true and apparent densities (p > 0.05, n=3, ANOVA). Representative SEM 
micrographs of C) PLGA + 40mg Mg, D) PLGA + 20mg Mg, E) PLGA + 10mg Mg and F) PLGA Only scaffold 
cross sections show an increasingly complex microstructure as Mg content decreases (Scale Bar = 200um for 
Figure 7C-F). 
 
2.3.4 Addition of Magnesium Particles to PLGA Scaffolds Buffers the Acidic Byproducts 
Produced throughout PLGA Degradation 
Measurement of the degradation medium pH yielded a significant decrease in pH for the PLGA 
Only scaffold group relative to all other groups as expected (Figure 8A). The PLGA Only 
degradation medium pH also exhibited a much larger standard deviation among samples than all 
other scaffold groups. The degradation medium of the Mg/PLGA scaffold groups exhibited a 
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small, but rapid increase in pH from the 1h timepoint to the 1d timepoint and then plateaued. After 
media refreshment began at 1wk, the pH of the PLGA + 10mg Mg group decreased until 4 weeks 
when there was no longer a significant difference between PLGA Only and PLGA + 10mg Mg 
groups (p > 0.01). The same trend occurred more slowly for the pH of the PLGA + 20mg Mg 
group which was no longer significantly different from the PLGA Only group at 7 weeks. The 
PLGA + 40mg Mg group exhibited a significantly increased pH compared to the PLGA Only 
group throughout the full 10 week experiment (p < 0.01). While the Mg/PLGA scaffold groups 
exhibited slightly elevated pH compared to the No Scaffold group, they did not experience the 
significant decrease in pH exhibited by the PLGA Only scaffold group. 
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Figure 8 The addition of Mg particles to PLGA scaffolds buffers the acidic byproducts produced 
throughout PLGA degradation while increasing amounts of Mg powder results in longer release times into the 
medium. Mg/PLGA scaffolds were placed in medium with FBS, which was replaced weekly, for 10 weeks. 
Media was sampled at 1h, 1d, 3d and weekly thereafter. A) The pH of the medium was measured immediately 
upon sampling (n=4, ANOVA with Dunnett’s post-hocs). Error bars are displayed on all data points; however, 
some are not clearly visible due to very small standard deviations. B) Media samples were diluted 20X in HBSS 
prior to Mg concentration measurement using ICP-AES. C) Representative PLGA + 20mg Mg and D) PLGA 
Only scaffolds prior to the 2w media sampling (Scale bar = 10mm for Figure 8C, D). 
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2.3.5 Increasing Amounts of Magnesium Particles in PLGA Scaffolds Result in Longer 
Magnesium Release Times 
Measurement of degradation medium magnesium concentration yielded similar trends to those 
observed in degradation medium pH. Magnesium was rapidly released into the medium over the 
first week (Figure 8B). Magnesium concentrations were similar among the Mg/PLGA scaffold 
groups at 2 weeks and then returned to baseline (0.8mM Mg in alpha-MEM) at timepoints 
corresponding to their return to baseline for pH measurement. The PLGA + 10mg Mg scaffolds 
returned to baseline at 4 weeks and the PLGA + 20mg Mg scaffolds returned to baseline at 6 
weeks. The PLGA + 40mg Mg scaffolds were still releasing Mg into the degradation medium at 
the end of the 10 week experiment. Interestingly, we observed an increase in size of the Mg/PLGA 
scaffolds (Figure 8C) throughout the degradation assay that was not observed with the PLGA Only 
scaffolds (Figure 8D). 
2.3.6 Bone Marrow Stromal Cells Cultured in Mg/PLGA Media Extracts Exhibited 
Increased Proliferation Compared to BMSCs Cultured in PLGA Only Media Extracts 
Cell proliferation in the indirect proliferation assay was varied among the scaffold types and the 
extraction dilutions (Figure 9). Culturing BMSCs in 1x extraction medium (no dilution) resulted 
in extensive cell death for all Mg/PLGA scaffold groups. However, the Mg/PLGA scaffold groups’ 
2x, 4x and 10x extraction medium dilutions did not negatively impact cell proliferation when 
compared to PLGA Only. Interestingly, BMSCs cultured in several of the magnesium-containing 
scaffold groups’ extracts (PLGA + 40mg Mg 10x, PLGA + 20mg Mg 4x and 10x and all PLGA + 
10mg Mg extract dilutions) exhibited increased proliferation compared to cells cultured in PLGA 
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Only extracts. Taken as whole, cell proliferation in each of the three Mg/PLGA scaffold groups 
was significantly increased (p < 0.01) compared to PLGA Only. 
 
Figure 9 Bone marrow stromal cells cultured in Mg/PLGA scaffold media extracts exhibited increased 
proliferation compared to BMSCs cultured in PLGA Only media extracts. Scaffolds were placed in alpha-
MEM + 16.5% FBS extraction medium for 72h. BMSCs were then cultured in 100%, 50%, 25% and 10% 
extraction medium for 6d after which an MTT assay was performed. While undiluted extracts of Mg/PLGA 
scaffolds inhibited proliferation, statistically significant increases in proliferation were observed for all three 
Mg/PLGA scaffold groups compared to PLGA Only due to proliferative effects of the 50%, 25% and 10% 
extracts (* p<0.01, n=6, ANOVA with Dunnett’s post-hoc). 
2.4 DISCUSSION 
The objective of this aim was to develop and characterize a porous metallic magnesium particle / 
PLGA scaffold for bone tissue engineering. We believe this is the first report of the synthesis of a 
porous metallic magnesium/polymer composite, as well as the first in vivo assessment of a metallic 
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magnesium/polymer composite in the bone environment. Our Mg/PLGA scaffolds buffered the 
acidic byproducts of PLGA degradation and increased BMSC proliferation. 
We successfully synthesized 3 different sizes of Mg/PLGA scaffolds using a solvent 
casting/salt-leaching method. We had optimized synthesis parameters as described in Table 5 and 
to provide scaffolds of similar size for the four compositions cast. Interestingly, following salt 
washout and lyophilization the PLGA + 10mg Mg and PLGA + 20mg Mg scaffolds exhibited a 
visible increase in diameter and length. This phenomenon was not observed in the PLGA Only or 
PLGA + 40mg Mg scaffolds. While we had minimized the salt washout time to avoid magnesium 
corrosion, it is likely that the saline environment within the two Mg/NaCl containing scaffold 
groups resulted in magnesium corrosion and subsequent hydrogen gas production within the 
scaffold. Increased salinity (particularly increased concentrations of Cl-) is known to increase 
magnesium corrosion which could explain why this increase in size is not observed in the PLGA 
+ 40mg Mg scaffolds (116). The evolution of hydrogen gas by the scaffolds during salt washout 
may have increased the pore volume of the PLGA + 10mg Mg and PLGA + 20mg Mg scaffolds 
resulting in the overall scaffold volume increase we observed for these two groups. However, our 
weight and SEM assessments of these scaffolds indicate that the overall corrosion of the 
magnesium particles was minor. 
We hypothesized that the addition of magnesium particles to the PLGA scaffolds would 
increase compressive strength and modulus compared to PLGA Only scaffolds, similar to 
observations by Cifuentes, et al (70). In fact, only the PLGA + 40mg Mg scaffolds exhibited higher 
maximum stress and modulus than the PLGA Only scaffolds. We suspect that the PLGA + 20mg 
Mg and PLGA + 10mg Mg did not exhibit increased strength and modulus due to the lesser 
amounts of magnesium and the more disrupted Mg/PLGA network from the salt washout. The 
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Mg/PLGA scaffolds tended to fail through cracking, thus the more disruptions in the Mg/PLGA 
network due to washed out NaCl particles, the more nucleation points that existed for failure to 
occur. This theory is supported by studies of PLGA Only scaffolds that show a rapid decrease in 
mechanical strength as porosity and pores size are increased (117). Also, more magnesium particle 
corrosion may have occurred in the PLGA + 20mg Mg and PLGA + 10mg Mg scaffolds during 
salt washout which could have resulted in decreased mechanical properties. While the PLGA + 
10mg Mg scaffold did not exhibit increased strength and modulus compared to PLGA Only 
scaffolds, its formability and mechanical properties proved sufficient for manipulation during in 
vivo surgical placement and still provided the necessary pH buffering properties, as well as an 
osteoconductive environment for bone growth. 
Our second hypothesis was that the addition of magnesium particles to PLGA scaffolds 
would buffer the acidic byproducts of PLGA degradation. The pH of medium containing PLGA 
Only scaffolds decreased significantly from baseline, as is expected with degrading PLGA (104, 
118, 119). We believe the larger standard deviation among samples in the PLGA Only group 
compared to other groups was due to small differences in the weight of PLGA in each scaffold and 
the lack of buffering by magnesium particles. While the medium pH of the Mg/PLGA scaffolds 
increased relative to baseline, this deviation was substantially smaller than the acidic deviation in 
the PLGA Only group. For this reason we accept our hypothesis that magnesium is capable of 
buffering the decreases in pH caused by PLGA degradation. Furthermore, even the PLGA + 10mg 
Mg scaffolds were capable of buffering the decrease in pH suggesting that small amounts of 
magnesium particles relative to PLGA are sufficient. Other groups have reported the use of 
magnesium salts as antacids to buffer pH decreases in degrading PLGA, thus improving drug 
release and protein stabilization (108, 109). Zhu, et al reported that in addition to directly buffering 
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acidic by-products of PLGA degradation, basic salts (including Mg(OH)2) decrease the 
autocatalytic degradation rate of PLGA (108) which could be desirable for slow-to-heal bone tissue 
engineering applications. 
Magnesium concentration in the degradation medium was also measured to determine the 
release rate of magnesium from the scaffold. As expected, the more magnesium particles contained 
in a scaffold, the longer magnesium was released from the scaffold. Higher amounts of magnesium 
contained in the scaffold did not result in a significantly higher concentration of magnesium in the 
medium at a given timepoint. One possible reason for this is that the medium volume was fixed at 
3ml and only replaced on a weekly basis. This could result in the magnesium concentrations 
between the scaffold and the medium reaching equilibrium, thus reducing magnesium degradation 
in the PLGA + 40mg Mg scaffolds. Another possible explanation is an increased disruption of the 
PLGA coating during the salt washout on individual magnesium particles which would limit their 
corrosive protective abilities as suggested by Ostrowski, et al (99). Another observation was the 
increase in size of the magnesium containing scaffolds which was not observed with the PLGA 
Only scaffolds. This is likely due to the continuing evolution of hydrogen gas from the degrading 
magnesium. If hydrogen gas is unable to immediately diffuse away from the scaffold interior, it 
may enlarge the pore volume, thus resulting in an overall increase in scaffold volume. This 
phenomenon will likely have to be considered when optimizing scaffold geometry and magnesium 
content in the future. The magnesium release profiles correspond well with the pH data as we 
expected. Additionally, the release time of the magnesium varied depending on the initial amount 
of magnesium. While in vivo study would be necessary to confirm this phenomenon, it suggests 
that scaffolds could be tailored to release magnesium for longer or shorter amounts of time 
depending on the application or anatomical site in which they would be used. 
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We were able to accept our hypothesis that Mg/PLGA scaffold extracts would increase 
BMSC proliferation compared to PLGA Only scaffold extracts. Undiluted extracts of the 
Mg/PLGA scaffolds resulted in nearly complete cell death which has been reported by other 
groups performing indirect cytocompatibility assessments of magnesium alloys (115). This 
cytotoxicity is primarily related to the non-physiological degradation rate that is experienced by 
magnesium during the extraction process and the resulting osmotic shock experienced by the cells 
when exposed to the extracts. As extracts were diluted, the magnesium concentration (and overall 
osmotic pressure) decreased resulting in an increased BMSC proliferation which has been reported 
in past studies to occur at 5-20mM Mg depending on cell type (73, 107, 120). The exact 
mechanisms of magnesium’s impact on cell proliferation are not fully understood, but support the 
improved bone regeneration observed with magnesium’s use in vivo. 
Analysis of the synthesized scaffolds showed that some magnesium particle corrosion may 
have occurred during salt washout. We plan on more fully investigating the synthesis process’ 
effect on the oxidation state of the magnesium particles in a future study. Our in vitro 
characterization of the Mg/PLGA scaffolds was limited in its investigation of the phenomenon of 
magnesium’s buffering of the PLGA scaffolds. Future work is planned to examine the scaffold 
microenvironment’s pH as a result of inclusion of the PLGA. Also planned are direct 
cytocompatibility assessments of BMSCs on the Mg/PLGA scaffolds. Additionally, these 
experiments will also allow us to examine the effects of Mg/PLGA scaffolds on the osteogenic 
gene expression of the BMSCs. 
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2.5 CONCLUSIONS 
Completion of this aim represented the first step towards development of a Mg/PLGA bone graft 
scaffold in support of this thesis’ overall goal of developing degradable Mg-based guided bone 
regeneration devices. Promising findings related to the non-acidic degradation profile and the 
increased proliferation of bone marrow stromal cells encouraged us to pursue in vivo testing of the 
Mg/PLGA scaffold in two different approaches. First, to assess the ability of the Mg/PLGA 
scaffold to support bone regeneration in a clinically relevant socket preservation model as 
discussed in Specific Aim 2. Second, a shorter-term murine intramuscular implantation model to 
assess the angiogenic and inflammatory responses to Mg/PLGA scaffolds at shorter time periods. 
Successful completion of both these approaches will not only reveal more about the potential genes 
and proteins that are affected by degrading magnesium, but also support the case for 
biocompatibility of magnesium in future regulatory filings. 
The work in this specific aim also formed the foundation for an invention disclosure filed 
with the University entitled “A composite magnesium/polymer scaffold to buffer pH changes and 
enhance tissue regeneration”. A non-provisional patent application was filed using this specific 
aim as supporting data as our group performed additional business and technology development 
described further throughout this thesis. 
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3.0  SPECIFIC AIM 2: EVALUATE THE THERAPUTIC POTENTIAL OF 
MAGNESIUM/PLGA SCAFFOLDS IN A CANINE SOCKET PRESERVATION MODEL 
Figure 10 Experimental overview of Specific Aim 2. 
 
Following evaluation of several Mg/polymer composite systems and selection of Mg/PLGA 
scaffolds and in vitro characterization of the scaffolds, an in vivo bone regeneration study was 
pursued (Figure 10). A canine socket preservation model was selected due to the low-risk nature 
of the intervention and the ability to demonstrate Mg/PLGA’s support of bone regeneration. Such 
demonstrations would be necessary to validate Mg/PLGA’s utility as a bone graft substitute for 
clinical use, as well as to support the development of other magnesium-based guided bone 
regeneration devices in the future. Finally, although not presented in this thesis, the histological 
samples derived from this study could be used for immunohistochemical approaches for evaluation 
of gene and protein activity within and surrounding the degrading Mg/PLGA scaffolds. This socket 
preservation model is therefore suitable for both evaluation of our novel Mg/PLGA scaffolds and 
elucidation of biological mechanisms affected by the presence and degradation of our Mg/PLGA 
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scaffolds. The in vivo evaluation of these magnesium/PLGA scaffolds was also described in: 
Brown A, Zaky S, Ray H, Sfeir C. Porous magnesium/PLGA composite scaffolds for enhanced 
bone regeneration following tooth extraction. Acta Biomaterialia 11(1): 543-53, 2015. Portions of 
the manuscript are reproduced here with permission of the publisher. 
3.1 INTRODUCTION 
Every year in the USA, 500,000 patients receive implant supported dental prostheses to restore 
functionality and cosmetic appearance of teeth extracted or lost due to poor oral hygiene, trauma 
and cancer. After a tooth is extracted, a blood clot is formed in the extraction socket which slowly 
remodels to provide a matrix suitable for bone ingrowth from the surrounding buccal bone. 
Unfortunately, numerous studies and clinical experience have shown that leaving this extraction 
socket empty, with only the blot clot formed, can lead to major bone resorption around the 
extraction site (121, 122). This lower quality and volume of bone is often not suitable for successful 
dental implant placement. Thus, sixty percent of these implant sites require some form of bone 
augmentation before or during implant placement to ensure sufficient bone quantity and quality 
for osseointegration and implant success (123-128).  
Socket preservation is one type of bone augmentation typically performed immediately 
following tooth extraction using a bone grafting and/or a guided tissue regeneration approach (129-
132). The bone grafting approach involves implantation of one of several biological or synthetic 
materials into the extraction socket prior to closing the gingival soft tissue. Biological materials 
used for this application include bone autografts (133, 134), mineralized and demineralized freeze-
dried bone allografts (134-136) and bone xenografts (137, 138). While bone autografts are 
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considered the gold standard grafting material due to their osteoinductivity and excellent 
outcomes, they suffer from defect size limitations, increased surgical time and costs and cause 
donor site morbidity (137, 138). Allografts and xenografts are commercially available in powder, 
particle, gel, sponge or block form and can be found in mineralized or demineralized compositions. 
These allografts and xenografts address cost and size limitations of autografts, but are not 
vascularized, can exhibit poor mechanical properties, are less osteoconductive and carry an 
increased risk of infection (139, 140). 
Synthetic bone grafting materials and composite materials have been developed more 
recently in attempts to overcome the drawbacks and limitations of autografts, allografts and 
xenografts. Most of these synthetic materials are calcium phosphate based in the form of 
hydroxyapatite and beta-tricalcium phosphate (140). These materials mimic the composition and 
characteristics of bone and are osteoconductive, but can inhibit full bone regeneration due to long 
degradation times (129, 141). Finally, several dental bone augmentation studies have used 
synthetic polymers, such as PLA or PLGA, as space fillers (142, 143) or barrier membranes (144, 
145) in and around the defect. PLGA is a highly studied polymer and its clinical use is widespread 
in materials ranging from sutures to vascular stents to bone scaffolds (104, 119, 146). PLGA also 
has the advantage of being capable of delivering drugs, proteins and growth factors to enhance 
bone healing in both oral-maxillofacial and general orthopedic applications (16, 104, 143, 147). 
While use of these polymers resulted in good clinical outcomes for bone regeneration overall, 
further studies have shown that the acidic by-products produced during their degradation can lead 
to increased inflammation and hamper efforts at concurrent drug, protein and growth factor 
delivery (119). 
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3.2 MATERIALS AND METHODS 
3.2.1 in vivo Study using a Canine Socket Preservation Model 
PLGA + 10mg Mg scaffolds were selected for further study in vivo because they were found to be 
the lowest containing Mg group that still provided an enhanced proliferative effect in vitro. Empty 
tooth socket defects were chosen as a control in order to contrast any biocompatibility issues in 
the scaffold healing site to the native healing site. Additionally, this surgical model allows for bone 
regeneration to occur in the empty defect control, thus allowing comparison of bone regeneration 
rates between groups. The study protocol was approved by the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. Mg/PLGA implanted defects and empty defects were 
randomly assigned in a split mouth design in the left or right mandibular third (P3) or fourth (P4) 
premolars in twelve female beagle dogs age 9-13 months old (Marshall BioResources USA). Eight 
week and sixteen week timepoints were assessed with 6 defects per group at each timepoint. 
3.2.2 Surgery, Animal Care and Sacrifice 
Animals were placed in ventral recumbency under isofluorane anesthesia. Rubber dams and dam 
clamps were placed on the mandibular first molar and second premolar exposing the P3 and P4 
premolars (Figure 11A). The mesial and distal roots of P3 and P4 were then separated by a diamond 
bur under irrigation. The distal root was luxated by a periotom and extracted using #13 European 
style forceps (Figure 11B). The mesial root was sealed with a glass ionomer restoration to prevent 
bacterial contamination of the remaining root. While there was some variation between individual 
animals, the approximate dimensions of the resulting conically shaped tooth socket defect were 
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11mm in depth and 5.5mm in diameter with the diameter being larger at the alveolar crest and 
tapering apically. This translates to an approximate defect volume of 0.2cm3. The empty distal 
sockets of P3 and P4 were filled with either 1.5 small PLGA + 10mg Mg scaffolds or left empty 
(Figure 11C). Buccal and lingual free gingivae were approximated for complete closure over the 
extraction socket with interrupted resorbable sutures (5/0 VICRYL, Ethicon, Bridgewater, NJ) 
(Figure 11D). Dogs were sacrificed after 8 and 16 weeks postoperative and the mandibular 




Figure 11 Implantation of magnesium/PLGA scaffolds was performed using a canine tooth extraction 
and socket preservation surgical model. A) Rubber dam placement on first molar and second premolar to 
prepare for operation on the third and fourth premolars. B) Distal roots of the third and fourth premolars were 
extracted (Following root canals for unrelated study). C) Mg/PLGA scaffolds were packed into empty socket 
defect (or no material for empty control group). D) Socket closure by interrupted sutures. 
 
3.2.3 Micro-CT Analysis 
Prior to scanning, the full mandibular explants were trimmed to separate P3 from P4 and the 
enamel on the crowns was ground off to reduce beam hardening artifact. The samples were scanned 
in an ex vivo uCT system (Skyscan 1172, Bruker-Skyscan, Belgium) at 10um voxel size, 60kVp 
beam energy, 400ms exposure, 10 frames averaged per view and 360 degrees angular range of 
scan. The 3D reconstruction of raw files was subsequently performed with Recon and processing 
and analysis was performed with CTAn (Skyscan). Preserved bone height in each socket defect 
was computed by connecting the plane between the alveolar crests mesial and distal to the defect 
(intercrestal plane) at the mid root level bucco-lingually (when the mesial root canal, including 
apical foramen, was wholly evident). The distance between the intercrestal plane and the preserved 
bone height was measured from the center of the socket defect. Bone height measurements were 
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averaged from 3 different sections for each defect. Defect bone volume was calculated by orienting 
the scans as sagittal sections (mesio-distally). The boundaries of the mesial root were set as limits 
of the sections to be analyzed. The upper and lower threshold levels were determined and the 
region of interest (ROI) was drawn around the remaining mesial root from the mesial to the distal 
alveolar crest. This ROI was then mirrored onto the defect space to represent the original volume 
of the extracted distal root. Bone volume calculation was performed using binarisation based on 
the defined thresholds for scan sections across the entire root thickness. This calculated bone 
volume in the defect was then divided by the total volume of remaining mesial root space to 
compute %BV/TV (Figure 12). 
Differences in bone height and bone volume percent, as measured with micro-CT were 
analyzed using a one-way ANOVA with Bonferonni post-hocs. 
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Figure 12 Schematic of bone volume and bone height determination from microCT slices of healing 
socket preservation defects. A) The remaining premolar tooth roots were traced and mirrored onto the defect 
area from which bone volume regenerated was calculated (red shaded area). B) The intercrestal plane was 
measured from the alveolar bone ridges (red line) and bone height was measured from the middle of the defect 
area (green line). 
 
3.2.4 Histology 
Following micro-CT, un-decalcified samples were embedded in Technovit 9100 New plastic 
according to manufacturer’s protocol (Heraeus Kulzer, Hanau, Germany). Following 
polymerization, plastic blocks were trimmed and 5um serial sections were obtained using a 
microtome and tape transfer technique (Leica RM2255, Leica, Buffalo Grove, IL) with tungsten-
carbide blade. 
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3.2.4.1 Goldner’s Trichrome Staining 
Goldner’s Trichrome staining was performed to examine general tissue morphology and 
composition of the samples. Staining solutions were obtained from Electron Microscopy Sciences. 
Sections were deacrylated in xylene and methoxyethylacetate, cleared with a descending ethanol 
series and then held in distilled water. Sections were incubated with hematoxylin, Ponceau-acid, 
Orange G-Phospho and Light Green then dehydrated with an ascending series of ethanol prior to 
mounting with Eurapal mounting medium. 
3.2.4.2 Von Kossa Staining 
Von Kossa staining was performed to confirm the presence of mineralized tissues observed with 
micro-CT. Staining was performed based on manufacturer’s protocol using solutions from 
American Master Tech (Von Kossa Stain Kit, Lodi, CA). Sections were deacrylated in xylene and 
methoxyethylacetate cleared with a descending ethanol series and then held in distilled water until 
staining commenced. Slides were incubated with 5% aqueous silver nitrate under UV light then 
incubated with 2% sodium thiosulphate, followed by 1% neutral red. Stained sections were then 
dehydrated through an ascending ethanol series and xylene prior to mounting with toluene-based 
mounting medium (Richard Allan Scientific, VWR, Radnor, PA). 
3.2.4.3 Chloroacetate Esterase Staining 
Chloroacetate esterase staining was performed to detect neutrophils as a marker of inflammation 
within the samples. Staining was performed based on manufacturer’s protocol using solutions from 
Sigma Aldrich (Naphthol AS-D Chloroacetate Kit). Sections were incubated in a coplin jar 
containing the staining solution (sodium nitrite, fast red violet LB base, TRIZMAL 6.3 buffer 
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concentrate, Napthol AS-D chloroacetate, distilled water) and incubated for 30min at 37˚C. 
Sections were then washed in distilled water and mounted using Fluoromount (Fisher Scientific). 
3.2.4.4 Microscopy 
Brightfield microscopy was performed with a Nikon TE 2000 microscope (Melville, NY) equipped 
with a Nikon DS-Fi1 camera. Micrographs were captured and background illumination and white 
balance corrections were performed using Nikon NIS Elements. 
3.3 RESULTS 
3.3.1 Implantation of PLGA + 10mg Magnesium into Canine Pre-molar Tooth Sockets 
Increased the Bone Height Compared to Empty Defects 
Surgeries were performed without complications and animals were extensively monitored 
throughout the entire experimental timeline. No post-operative infections, severe inflammation or 
gas bubble formations were noted around the surgical sites. All dogs returned to a normal diet and 
displayed no mastication difficulties and experienced no weight loss post-operatively. 
Additionally, no abnormal behavior indicative of pain was noted by the veterinary staff.  
Defect bone height at 8 weeks post-implant was found to be 1.9mm and 2.2mm (Figure 
13E) below the intercrestal plane for the PLGA + 10mg Mg (Figure 13A) and empty defects 
(Figure 13C), respectively. At 16 weeks post-implant, bone height in both groups had increased 
compared to the 8 weeks timepoint. The bone height below the intercrestal plane was found to be  
0.9mm and 1.6mm for PLGA + 10mg Mg (Figure 13B) and empty defects (Figure 13D), 
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respectively. Overall, bone height was found to be better preserved by the Mg/PLGA scaffold 
compared to the empty defect (p < 0.05). 
Bone volume as a percent of total defect volume at 8 weeks was higher for PLGA + 10mg 
Mg than empty defects (29% vs. 21%); however, this increase was not statistically different 
(Figure 13F). Similarly, at 16 weeks, bone volume as a percent of total defect volume was 39% 




Figure 13 Implantation of PLGA + 10mg Mg scaffolds into canine pre-molar tooth sockets increased 
the bone height compared to empty defects. 8 week timepoint: A) PLGA + 10mg Mg, C) Empty defect. 16wk 
timepoint: B) PLGA + 10mg Mg and D) Empty defect. E) The bone height from the center of the defect to the 
intercrestal plane was measured and found to be significantly increased in the PLGA + 10mg Mg group (p<0.05, 
n=6, ANOVA). F) The remaining root outline was superimposed onto the extracted root defect and bone volume 
as a percentage of total volume was measured and no significant differences were found. 
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3.3.2 Histological Analysis of Defects Receiving PLGA + 10mg Mg Implants Confirmed 
Bone Ingrowth and Showed Typical Tissue Morphology 
Goldner’s Trichrome staining displayed similar and typical tissue morphologies for PLGA + 10mg 
Mg (Figure 14A) and empty defects (Figure 14B) at 8 weeks. A porous trabecular bone structure 
(green) was observed throughout the bone defect extending from the remaining tooth root and the 
adjacent tooth root. Mineralizing osteoid (purple) was identified in proximity to the mineralized 
bone. Healthy gingival tissue was observed overlying the bone in all samples; however, gingival 
soft tissue can be seen invading the bone defect space of the empty defect sample in Figure 14B. 
The marrow space showed normal morphology and blood vessels were observed. There were no 
signs of inflammation among any samples. At 16 weeks, a denser bone volume was observed in 
the defect space and mineralizing osteoid was again identified. All other tissue morphology 
appeared normal and was similar to the 8 week samples. Finally, no remnants of magnesium 
particles or PLGA were identified at 8 week or 16 week timepoints. 
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Figure 14 Bone volume in tooth root defect increased among both groups from 8wk to 16wk, but was 
not significantly different between groups. Goldner’s Trichrome staining was performed on 5um plastic 
sections for the 8wk A) PLGA + 10mg Mg and B) Empty defects, as well as the 16wk C) PLGA + 10mg Mg and 
D) Empty defects. Green – Mineralized Bone, Purple – Osteoid, Orange – Collagen (n=6). 
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The Von Kossa staining confirmed the mineralized bone identified with the Goldner’s 
Trichrome staining and micro-CT analysis (Figure 15). A more dense bone volume was observed 
at 16 weeks for both groups when compared to the 8 weeks timepoint. 
 
Figure 15 Bone volume in tooth root defect increased among both groups from 8wk to 16wk, but was 
not significantly different between groups. Von Kossa staining was performed on 5um plastic sections for the 
8wk A) PLGA + 10mg Mg and B) Empty defects, as well as the 16wk C) PLGA + 10mg Mg and D) Empty 
defects. Black – Mineralized Bone, Red/Pink – Nuclei (n=6). 
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3.3.3 No Significant Chronic Inflammation was Observed in any of the Experimental 
Groups 
Chloroacetate Esterase staining was performed to identify neutrophils, a marker of inflammation. 
Occasional positively stained cells were identified in the space surrounding mineralized tissue in 
the bone defect (Figure 16). No significant collections of positive staining were identified in any 
of the groups at either timepoint. 
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Figure 16 No significant collections of positive staining neutrophils were identified in any of the groups 
at either timepoint suggesting the absence of chronic inflammatory response. Chloroacetate esterase staining 
was performed on 5um plastic sections for the 8wk A) PLGA + 10mg Mg and B) Empty defects, as well as the 
16wk C) PLGA + 10mg Mg and D) Empty defects. Neutrophils – Brown (n=6). 
3.4 DISCUSSION 
The objective of this aim was to evaluate the in vivo bone regeneration capabilities of our novel 
porous Mg/PLGA scaffolds. We believe this is the first reported in vivo evaluation of a 
magnesium-based dental bone grafting therapy. We successfully performed the socket 
preservation defect creation and repair surgeries and the Mg/PLGA scaffolds fit within the typical 
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clinical workflow. Qualitative feedback from our clinicians during the repair surgeries suggests 
that the current form of our Mg/PLGA scaffolds is suitable for clinically observed socket 
preservation procedures. No adverse events were observed in the immediate post-operative period 
nor during the 8 and 16 week healing periods. These observations are promising for the further 
development of the Mg/PLGA scaffold as a dental bone grafting substitute. 
Our hypothesis that Mg/PLGA scaffolds would be safe and effective at regenerating bone 
was supported through our micro-CT and histological analyses. Defects that were treated with 
Mg/PLGA scaffolds had an improved bone height preservation compared to empty defects at both 
8 and 16 weeks post-surgery. This effect compares well with other bone grafting materials 
(including polymers) that have been successfully used for socket preservation (124, 142). While 
the difference was not significant, defects treated with Mg/PLGA exhibited an increased bone 
volume compared to empty defects. Additional support for the biocompatibility of the Mg/PLGA 
scaffolds was provided through the lack of inflammation and presence of normal tissue 
morphology noted in our histological analyses. Overall, our in vivo findings suggest that 
Mg/PLGA scaffolds could be used to safely and effectively regenerate bone. 
Limitations of this study include the lack of a PLGA Only control group and clinical gold 
standard control group in the in vivo socket preservation experiment. The current in vivo study 
focused only on establishing safety and effectiveness of the Mg/PLGA scaffold in a bone 
environment. Future experiments will include both a PLGA Only control group and a gold standard 
bone graft control group to examine the comparative effectiveness of Mg/PLGA scaffolds. 
Additionally, the socket preservation model is not a critical-sized defect; thus, we plan to explore 
the capabilities of Mg/PLGA scaffolds in orthopedic applications using a rabbit ulnae defect 
model. Our in vivo study was limited to 8 week and 16 week timepoints, well after any early stage 
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inflammation would have occurred. While the dogs implanted with this material showed no 
clinical issues post-implant, including the lack of gas pocket formation during our weekly 
observation, we plan on performing additional experiments with earlier timepoints to assess short-
term tissue response to the Mg/PLGA scaffolds. 
Finally, the explanted samples from this study will be used for a comprehensive 
immunohistochemical assessment to further elucidate the biological mechanisms affected by 
degrading magnesium. Work by Chaya, et. al., suggests that magnesium induces bone formation 
surrounding magnesium implants where there was previously not bone present (76, 148). Several 
other groups have found increased bone depositions and osteogenic gene and protein expression 
surrounding magnesium devices compared to polymeric devices (59, 60, 62, 149). These studies 
suggest that periosteal cells may play a major role in bone regeneration observed around degrading 
magnesium devices in vivo. In the future we will use these explants to assess the interface between 
the degrading Mg/PLGA scaffolds and the periosteum. These samples could be used to support 
the in vitro investigation in discussed in Specific Aim 3 by assessing in vivo the genes and proteins 
identified as being activated in vitro. The conclusions of this study strengthened the overall 
hypothesis of this thesis that a magnesium/PLGA composite guided bone regeneration platform 
would yield improved clinical utility over currently used devices. 
3.5 CONCLUSIONS 
Specific Aim 2 of this thesis established the first in vivo evidence of Mg/PLGA composites’ ability 
to regenerate bone in a clinically relevant model. Combined with the in vitro evaluations presented 
in Specific Aim 1, this study was presented at the 6th Symposium on Biodegradable Metals in 
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Maratea, Italy (150). This work encouraged us to pursue the development of a Mg/PLGA barrier 
membrane and micromesh as the next pieces in our guided bone regeneration platform. Given our 
success at regenerating bone in a low-risk socket preservation model, we were also encouraged to 
explore bone regeneration capabilities in more severe bone defects. These next steps are presented 
in Specific Aim 4. 
The in vivo findings in this specific aim, as well as increasing interest from industry, 
supporting converting our provisional patent application to a PCT (151). Several entrepreneurial 
resources within the University of Pittsburgh where engaged following the completion of the 
specific aim to help support additional research.  
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4.0  SPECIFIC AIM 3: EVALUATE THE OSTEOGENIC, ANGIOGENIC AND 
INFLAMMATORY GENE EXPRESSION PROFILE OF HBMSCS EXPOSED TO 
MAGNESIUM 
Following evaluation of our Mg/PLGA composite bone graft scaffold in both in vitro and in vivo 
environments, we set forth on evaluating potential biological mechanisms to explain the enhanced 
bone regeneration we observed. As part of this research’s broader context within the 
Revolutionizing Metallic Biomaterials Engineering Research, we evaluated the impact of common 
alloying elements on cell proliferation to help better inform alloy design. However, we focused 
specifically on magnesium due to the cost and time necessary to examine gene and protein 
pathways comprehensively. Ideally, specific concentration ranges of magnesium could be 
identified that maximize osteogenic pathway activation and these findings could be incorporated 
into design criteria. While such a goal is likely not to be reached in the near future, we aimed to 
contribute to the growing body of evidence supporting not only magnesium’s osteogenic 
enhancing effects, but its biocompatibility in support of future regulatory applications. Portions of 
this work were presented in several conference posters and compiled into a manuscript: Yoshizawa 
S, Brown A, Barchowsky A, Sfeir C. Magnesium ion stimulation of bone marrow stromal cells 
enhances osteogenic activity, simulating the effect of magnesium alloy degradation. Acta 
Biomaterialia 10(6): 2384-42, 2014. 
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4.1 INTRODUCTION 
Every year, more than 6.2 million cases of bone fracture are reported with 56% of fractures in 
adults requiring internal fixation with biomedical devices such as plates and screws (152, 153).  
Bone fixation devices are most commonly made of non-degradable metallic alloys, such as 
titanium and stainless steel.  Drawbacks to these traditional orthopedic alloys include stress 
shielding due to the mismatch in mechanical properties between the metal and the bone (154), as 
well as a need for secondary surgery to remove the fixation devices in some cases. Degradable 
polymers (e.g. poly-lactic-co-glycolic acid (PLGA), poly-L-lactic acid (PLLA), and poly-ethylene 
glycol (PEG)) have been employed in order to avoid the secondary removal surgery; however, 
their compressive strengths are not ideal for load bearing fracture repair cases (155) and foreign 
body reactions to the polymers have been reported (156-158). In order to address these issues, 
magnesium (Mg) alloys have been studied as a candidate material for bone fixation devices due to 
their bone-like mechanical properties, enhanced osteoconductivity when compared to polymers 
and ability to safely degrade in vivo (154). 
Mg alloys were first used for biomedical applications over 200 years ago; however, their 
development has accelerated in the last ten years due to advances in alloy manufacturing and 
processing methods (50).  Numerous research groups have synthesized a wide range of magnesium 
alloys and characterized their microstructure, corrosion properties, mechanical properties, in vitro 
cytotoxicity and in vivo biocompatibility. In vivo Mg alloy studies have involved implantation of 
rods into rabbit tibiae (159), ulnae (160) and femora (54, 56), rat femora (161) and guinea pig 
femora (73, 162). These in vivo studies found through micro-computed tomography, mechanical 
testing and histology analysis that the magnesium alloys safely degrade and allow osseointegration 
at the site of implantation. Additionally, comparisons of Mg alloy rods to polymer rods found that 
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mineralization was increased surrounding the Mg samples (162). Mg2+ concentrations were found 
to be increased in bone tissue immediately surrounding degrading Mg alloys in vivo (163). This 
finding suggests that the mechanisms underlying enhanced bone regeneration observed in vivo can 
be recapitulated using Mg2+ salts in vitro. 
Most in vitro studies of Mg alloys have focused on cell viability and proliferation to assess 
cytocompatibility.  Previous studies used MTT and WST-1 assays to show that Mg alloys are 
cytocompatible with primary human mesenchymal stem cells (160), bone derived cells (72), 
mouse fibroblasts (51, 56), MG-63 human osteosarcoma cells (72, 164), RAW264.7 macrophages 
(72) and MC3T3-E1 osteoblasts (51, 165).  In addition, von Kossa and alkaline phosphatase stains 
were utilized to examine the effect of magnesium alloys on U2OS human osteosarcoma cell 
mineralization and osteogenic differentiation (74).  Furthermore, immunohistochemistry and flow 
cytometry were employed to study the mechanisms of cell adhesion on biomaterials when 
stimulated by Mg (166).  Overall, these in vivo studies have shown Mg-based devices to be 
promising for bone fracture fixation and in vitro studies have shown enhancement of standard 
osteogenic markers in bone cells.  However, to the best of our knowledge, this report is the first 
identification of specific intracellular signaling pathways through which Mg enhances bone 
regeneration. 
We hypothesized that treating human bone marrow stromal cells (hBMSCs) with MgSO4, 
resulting in increased exposure of the cells to Mg2+, would enhance osteogenic gene expression, 
matrix production and mineral deposition. We cultured hBMSCs with a large range of magnesium 
concentrations then used the proliferation findings to identify three concentrations of magnesium 
to expose hBMSCs to for more in-depth biological studies. We cultured hBMSCs with these 
various concentrations of MgSO4, either with or without osteogenic factors.  These treated cells 
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were then analyzed for their matrix mineralization, gene expression and protein production in order 
to elucidate the intracellular signaling pathways involved in bone growth around Mg alloys.  In 
this study, we found that increased MgSO4 enhanced protein expression of collagen type X 
(COL10A1), vascular endothelial growth factor (VEGF), hypoxia inducible factor (HIF)-1α, HIF-
2α, and peroxisome proliferator-activated receptor gamma, coactivator (PGC)-1α in hBMSCs.  
COL10A1 is abundant in fractured bone at early stages of healing and VEGF is a major angiogenic 
signaling protein.  This work identified specific osteogenic pathways that are affected by Mg. 
Identification of these pathways and the optimal Mg concentrations to enhance their activity will 
lead to improved Mg bone fixation device design and other possible therapeutic uses for Mg. 
4.2 MATERIALS AND METHODS 
4.2.1 Harvest, Expansion and Experimental Culture of Human Bone Marrow Stromal 
Cells (hBMSCs) 
hBMSCs were harvested from surgical waste in accordance with the US NIH regulations 
governing the use of human subjects under protocol 94-D-0188 or OHRS Assurance No. 4165, 
and established from colony forming units as previously reported (167), and the osteogenic 
differentiation capabilities of these cells were confirmed by bone tissue formation following in 
vivo transplantation into immunocompromised mice (courtesy of Dr. Pamela Robey at National 
Institutes of Health).  The cells were plated at 40,000 per cm2 in Minimum Essential Medium Eagle 
(MEM) Alpha Modifications (α-MEM) (Life Technologies, Grand Island, NY) containing 20% 
fetal bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA), 1% penicillin and streptomycin 
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(Life Technologies) and 1% L-glutamine (Life Technologies).  We used this medium formulation 
as “expansion medium”.  Cells were cultured at 37°C in an atmosphere of 5% CO2. Non-adherent 
cells were washed away twenty-four hours later.  For subculture, hBMSCs were detached with 
0.05% of trypsin - EDTA (Life Technologies), and expanded at a 1:3 ratio.  Cells were passaged 
three times, harvested, and then plated for experiments.    
hBMSCs were cultured in either maintenance or osteogenic medium throughout 
experiments.  “Maintenance medium” consisted of α-MEM, 5% FBS, 1% penicillin/streptomycin, 
1% L-glutamine and a variable amount of MgSO4 (5, 10, and 20 mM for Alizarin red staining 
assay, 10 and 100 mM for proliferation assay and 10 mM for gene and protein expression analysis) 
(Sigma Aldrich, St. Louis, MO).  α-MEM, as-purchased, contains 0.8 mM of MgSO4 (the 0.8mM 
concentration of MgSO4 will be considered the control group).  Osteogenic differentiation of 
hBMSCs was induced by culturing in “osteogenic medium” which contained α-MEM, 5% FBS, 
1% penicillin/streptomycin, 1% L-glutamine, 50μM ascorbic acid, 100nM dexamethasone, and 
10mM β-glycerol phosphate (Sigma-Aldrich, St. Louis, MO).  Finally, a “SO42- control medium”, 
was formulated in the same manner as the maintenance medium, but with substituted MgSO4 to 
Na2SO4 (Fisher Scientific, Pittsburgh, PA).  
4.2.2 Differentiated and Undifferentiated Cell Proliferation Assay – Trypan Blue 
1X105 hBMSCs were plated per well in 6 well plates in expansion medium.  After twenty-four 
hours, the medium was switched to maintenance or osteogenic medium containing 0.8, 10 or 100 
mM MgSO4 with 3 biological replicates per group.  Cells were detached with 0.05% of Trypsin - 
EDTA (Life Technologies) at 1, 3, 5 and 7 days, and the number of live cells was counted using a 
hemocytometer.  The dead cells were excluded using the trypan blue stain.  
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4.2.3 Alizarin Red Staining 
hBMSCs were plated in 6 well plates at a density of 1X105 cells per well in expansion medium.  
Twenty-four hours after plating, the medium was switched to 0.8, 5, 10 or 20 mM MgSO4 
osteogenic medium or Na2SO4 (SO42- control medium) with 3 biological replicates per group and 
cultured for three weeks.    The cells were then fixed in 10% formalin for one hour and washed 
with PBS.  The calcium nodules in extracellular matrix (ECM) were stained with a solution of 1% 
Alizarin Red (Sigma Aldrich) in 2% ethanol for 5 minutes.  Following incubation, the stain was 
removed and washed repeatedly with ddH2O.  Finally, the amount of Alizarin Red bound to the 
calcium nodules was quantified by dissolving the stained ECM into 1% cetylpyridinium chloride 
(CPC) solution and reading the optical density at 540 nm using a plate reader (Spectramax 190, 
Molecular Devices, Sunnyvale, CA). 
4.2.4 Assessment of Gene Expression 
4.2.4.1 RNA Extraction and Purification 
hBMSCs were plated in 6 well plates at a density of 1X105 cells per well in maintenance or 
osteogenic medium (0.8 and 10 mM MgSO4) with three biological replicates per group and 
cultured for three weeks. Total RNA was extracted and purified using RNeasy Mini Kit (Qiagen, 
Valencia, CA) and treated with RNase-free DNase (Qiagen) to eliminate genomic DNA according 
to manufacturer’s instructions. The quantity and quality of RNA was measured using a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Waltham, MA).  Total RNA samples were cleaned 
using RNA Clean & Concentrator™-5 (Zymo Research Corporation, Irvine, CA) until the ratio of 
absorbance readings at 260nm to 230nm was greater than 1.7, and 260 nm to 280 nm was between 
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1.8 and 2.0 according to manufacturer’s instructions for quantitative PCR (qPCR) arrays 
(SABiosciences, Frederick, MD).  
4.2.4.2 Quantitative PCR Array 
500ng of purified RNA from each sample were reverse transcribed to cDNA using RT2 First Strand 
Kit (SABiosciences) according to the manufacturer’s instructions. qPCR array assays were 
performed using RT2 ProfilerTM PCR Array: Osteogenesis (SABiosciences) and 7900HT Fast 
Real-Time PCR System (Applied Biosystems, Carlsbad, CA) according to manufacturers’ 
instructions.  Briefly, each experimental cDNA sample was mixed with RT2 SYBR Green Master 
Mix and RNase-free water then plated into 96 wells of the 384 well qPCR array.  The qPCR array 
is pre-filled with 4 replicates of 84 different primer/probe sets of osteogenesis related genes, 4 
different primer/probe sets of housekeeping genes, one genomic DNA control, three reverse 
transcription controls and three positive PCR controls.  The thermal cycler was set to incubate one 
time at 95°C for 10 minutes for activation of HotStart DNA Taq Polymerase.  Amplification of 
DNA was performed for 40 cycles consisting of 95°C denaturing for 15 seconds and 60°C 
annealing for 1 minute.  The fluorescence intensity for all wells was collected at the end of each 
cycle.  The Ct values were calculated by the first cycle that the fluorescent data of each well was 
greater than the fixed threshold.  Ct values were analyzed by ΔΔCt method as previously described 
(168).  All Ct values greater than 35 were considered negative calls.  Ct values of each sample were 
normalized with the average Ct values of housekeeping genes (ΔCt value).  The difference of the 
ΔCt value between the experimental and control wells was used as the ΔΔCt value.  The fold change 
between these two wells was calculated as 2(-ΔΔCT).  
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4.2.4.3 Quantitative PCR  
mRNA expression of HIF1A, HIF2A, COL10A1, and 18S ribosomal RNA was analyzed by 
TaqMan ABI inventoried gene assays (Applied Biosystems) to confirm the mRNA expression data 
from qPCR arrays.  VEGFA (NM_003376) was designed using Prime Express Software from ABI, 
Version 2.0 (Forward 5’-CATGCAGATTATGCGGATCAA-3’, reverse 5’-
TTTGTTGTGCTGTAGGAAGCTCAT-3’, Taqman probe 5’-
CCTCACCAAGGCCAGCACATAGGAGA-3’).  Real time PCR reactions were conducted in 
7900HT Fast Real-Time PCR system (Applied Biosystems). 
4.2.5 Western Blotting 
hBMSCs were plated into 6 well plates at a density of 1x105 cells per well and cultured for three 
weeks in maintenance or osteogenic medium (0.8 and 10 mM MgSO4) with 3 biological replicates 
per group.  Proteins from cultured cells and ECM were extracted using M-PER® Mammalian 
Protein Extraction Reagent (Thermo Fisher Scientific).  The amount of proteins was quantified by 
colorimetric protein assay using Pierce® 660 nm Protein Assay Reagent (Thermo Fisher 
Scientific).  The protein samples were reduced with sample buffer containing β-mercaptoethanol 
at 60˚C for 10 min, and SDS-PAGE was performed with a 10% acrylamide gel.  The proteins were 
transferred to polyvinyl difluoride (PVDF) membrane (Bio-Rad, Hercules, CA), and Western 
blotting was performed using primary antibodies against COL10A1 (C7974), β-actin (A5441) 
(Sigma-Aldrich), VEGF (NB100-648),  HIF-2α (ΝΒ100−122), PGC-1α (ΝΒΠ1−04676) (Novus 
Biologicals, Littleton, CO), and HIF-1α (BD Transduction Laboratories, Franklin Lakes, NJ).  The 
secondary antibodies were HRP conjugated anti-mouse IgG or anti-rabbit IgG (R&D Systems, 
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Minneapolis, MN) or anti-mouse IgM (Santa Cruz Biotechnology).  The blots were developed 
with the Western Lightning® Plus-ECL (PerkinElmer, Inc., Waltham, MA).  The intensity of the 
bands were measured by ImageJ, and normalized by β-actin. 
4.2.6 Statistical Analysis  
The graphical presentations of data show the means ± standard deviations. The proliferation assay 
and Alizarin Red staining data were analyzed using a one-way ANOVA followed by post-hoc t-
tests. The p-values from the PCR array were calculated based on Student’s t-tests of the replicate 
2-∆Ct values for each gene in the control group and treatment groups.  Student’s t-tests were also 
performed to calculate the differences in the optical intensities of specific western blot bands 
obtained from cells treated with either 0.8 mM or 10 mM MgSO4.  
4.3 RESULTS 
4.3.1 5 to 10 mM of MgSO4 Induced Higher Cell Proliferation Rate and Extracellular 
Mineralization.  
Cell proliferation rates of hBMSCs were significantly enhanced when grown in medium 
containing 10 mM of MgSO4 in both maintenance and osteogenic medium (Figure 17), but were 
inhibited at 100 mM MgSO4.  Stronger Alizarin Red staining was observed in the wells treated 
with 5 and 10 mM of MgSO4 (Figure 18 A and B).   In comparison, Na2SO4 groups had fewer 
numbers of nodules, and lighter Alizarin Red staining of the ECM.  The quantified optical density 
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of Alizarin Red dissolved in CPC solution was significantly higher in the 5 and 10 mM MgSO4 
groups when compared to Na2SO4 control (Figure 18 C). 
 
Figure 17 Result of cell count by Trypan blue assay shows proliferation rate of hBMSCs after 
stimulation with 0.8 mM (original concentration in the culture medium), 10 mM, and 100 mM of MgSO4 
contained medium.  Statistical significance was observed between all three different concentration of MgSO4 




Figure 18 5 and 10 mM of MgSO4 induced higher deposition of mineral into ECM.   A. Alizarin red 
staining of ECM of hBMSCs after 3 weeks of culture in osteogenic medium containing 0.8, 5, 10 and 20mM of 
MgSO4 or Na2SO4.  B. 10x images of ECM stained with Alizarin red.  Scale bar is 200 µm.  C. The amount of 
Alizarin red was quantified by dissolving into 10% CPC solution.  The relative OD at 562 nm to control is 
shown. 
 
4.3.2 10 mM MgSO4 Enhanced COL10A1 and IGF2 Expression and Decreased ITGA3 
Expression 
The qPCR array assays yielded 14 out of 81 genes up or downregulated by greater than 2.0 fold 
when cultured in 10 mM MgSO4 compared to 0.8 MgSO4. The expression levels of all the genes 
are listed in Supplemental Table 1.  Among them, collagen type X (COL10A1), insulin like growth 
factor 2 (IGF2), and integrin α3 (ITGA3) showed statistically significant difference of 
up/downregulation.  hBMSCs treated with 10 mM of MgSO4 expressed significantly higher 
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amounts of COL10A1 when cultured in both maintenance and osteogenic medium compared to 
0.8 mM MgSO4. The expression of COL10A1 was increased by 2.5 and 4.0 folds, respectively, in 
maintenance and osteogenic medium (Figure 19A and B). In addition, the expression of IGF2 was 
increased by 2.4 fold when cultured in 10 mM MgSO4 maintenance medium compared to 0.8 mM 
MgSO4 maintenance medium. Furthermore, the expression of ITGA3 in the osteogenic medium 
with 10 mM MgSO4 was decreased by 0.42 fold compared to cells cultured in 0.8 mM MgSO4 
(Figure 19 A and B).  The other genes upregulated in 10 mM MgSO4 were collagen type III 
(COL3A1), matrix metalloprotease (MMP)-8, growth differentiation factor-1 (GDF1), cartilage 
oligomeric matrix protein (COMP),  collagen type XI (COL11A1), MMP2, cathepsin K (CTSK), 
and Twist-related protein 1  (TWIST1) (more than 2.0 fold). The genes downregulated were 
alkaline phosphatase (ALPL), vascular cell-adhesion molecule-1 (VCAM1), and collagen type XII 
(COL12A1) (less than 0.5 fold) (Figure 19A and B).  
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Figure 19 10 mM Mg ion enhanced COL10A1 and IGF2 expression and decreased ITGA3 expression.  
hBMSCs were cultured in maintenance or osteogenic medium with 0.8 mM (control) or 10 mM MgSO4 for 
three weeks.  The osteogenic mRNA expression was analyzed by quantitative PCR arrays.  The genes listed 
were fold change >2 or <0.5 and Ct value was <30.  COL2A1 data is shown to prove that hBMSCs did not 
differentiated towards chondrogenic cells.  n=3.  A) mean fold change of 10 mM Mg ion groups compared to 
0.8 mM Mg ion (control) groups,  B) mean fold change and p-value. 
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4.3.3 qPCR Validation of COL10A1 and VEGF and Expression Levels of HIF2A 
The mRNA expression of COL10A1 and VEGF was confirmed by qPCR showing significantly 
increased mRNA expression levels in the 10 mM MgSO4 groups in both maintenance (1.3 fold) 
and osteogenic (2.6 fold) medium when compared to 0.8 mM (Figure 20). However, there was no 
significant change in VEGF expression by 10 mM MgSO4 (Figure 20).  In addition, we examined 
the HIF1A and HIF2A mRNA expression, since they were reported as the most potent 
transcriptional activators of COL10A1 expression (169). However, we did not observe a change in 
mRNA expression of HIF1A and HIF2A in 10 mM MgSO4. As discussed below, upon literature 
examination (170), it was shown that HIF1A and HIF2A are modulated at the protein level.  Thus, 
we performed Western blot analysis to determine protein expression levels following the treatment 
with MgSO4. 
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Figure 20 10 mM MgSO4 changed COL10A1 but not VEGFA, HIF1A and HIF2A mRNA expression.  
hBMSCs were cultured in maintenance or osteogenic medium with 0.8 mM (control) or 10 mM Mg ion for 1, 2 
and 3 weeks.  The mRNA expression of COL10A1, VEGFA, HIF1A, and HIF2A was analyzed by the 
quantitative PCR.  0.8 M: 0.8mM MgSO4 contained maintenance medium, 10 M: 10 mM MgSO4 contained 
maintenance medium, 0.8 O: 0.8mM MgSO4 contained osteogenic medium, 10 O: 10 mM MgSO4 contained 
osteogenic medium.  n=3.  *p<0.05 with Student’s t-test between two samples indicated with a bar. 
 81 
4.3.4 10 mM MgSO4 Enhanced COL10A1, VEGF, HIF-1α, HIF-2α, and PGC-1α Protein 
Expression 
The protein expression of hBMSCs cultured in MgSO4 for three weeks was analyzed by Western 
blotting. Although statistically significant change was observed only in maintenance medium 
group, expression of COL10A1 was enhanced 1.5 to 1.9 fold in cells cultured with 10 mM MgSO4 
in maintenance medium, relative to control (Figure 21A and B), confirming that Mg enhances 
osteogenic differentiation.  VEGF (an important osteogenic factor) expression was also increased 
by 10 mM MgSO4 under both culture conditions.  Since both COL10A1 and VEGF are 
transcriptionally activated by HIF-1α and HIF-2 α, we examined their protein expression and 
found that only HIF-2 α levels were increased by 10 mM MgSO4 in maintenance medium, 
however the increase was not statistically significant (Figure 21A and B).  In contrast, protein 
levels of PGC-1 α, another important transcriptional activator of VEGF, increase in osteogenic 
medium with 10 mM MgSO4 (Figure 21A and B). 
 82 
Figure 21 10 mM Mg ion enahnced collagen type X, VEGF, PGC-1α, HIF-1α, and HIF-2α protein 
expression.  hBMSCs were cultured in maintenance or osteogenic medium with 0.8 mM (control) or 10 mM 
MgSO4 for three weeks.  The protein expression level was analyzed by Western blotting, and quantified by 
ImageJ.  Bar graph represent the ratio of expression level of 10 mM MgSO4 samples compared to 0.8 mM 
MgSO4 samples in the same kind of medium (maintenance or osteogenic).  n=3.  *p<0.05 with Student’s t-test 
compared to 0.8 mM MgSO4 samples in the same kind of medium (maintenance or osteogenic). 
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4.4 DISCUSSION 
The data show that hBMSCs proliferate faster, and their extracellular matrix mineralized more in 
vitro when 10mM of MgSO4 was added.  Using the time points and Mg concentrations of 10 mM 
that showed the highest Alizarin Red staining, we then performed quantitative PCR arrays to 
analyze osteogenic gene expression and determined that COL10A1 (ECM component of healing 
bone) gene expression was increased in both undifferentiated (2.5 fold) and osteogenic-
differentiated (4.0 fold) human bone marrow stromal cells.  The data obtained in these studies 
support the hypothesis that increasing Mg2+ enhances hBMSCs, osteogenic gene expression, 
matrix production, and mineral deposition. 
In this study, hBMSCs proliferated 1.2 times more in 10 mM MgSO4 medium, relative to 
medium with 0.8 mM MgSO4.  This finding is consistent with a previous report that the 
proliferation rate of human articular chondrocytes (73), and microvascular endothelial cells (171) 
was enhanced at 5 to 10 mM of MgSO4 .  The proliferation is inhibited at higher concentration 
(>20 mM) of MgSO4 in this study.  We speculate that this is because of the cytotoxicity of Mg 
ion, as various kinds of metal ion (Na, Cr, Mo, Al, Ta, Co, Ni, Fe, Cu, Mn, and V) are reported to 
have cytotoxic effects on osteoblasts at certain concentrations as well (172).  As shown in the 
Alizarin Red staining data, 10 mM MgSO4 stimulation resulted in the largest increase in ECM 
mineralization compared to control medium. Previous reports have shown the addition of 5 to 10 
mM MgSO4 to tissue culture medium enhanced glycosaminoglycan production, and 
redifferentiation (upregulation of collagen type I and melanoma inhibitory activity: MIA) of 
human articular chondrocytes (73).  These findings are consistent with our data showing that 5 to 
10mM of MgSO4 were the most effective concentrations for stimulating ECM mineralization.  In 
addition, Liu, et. al. have also shown increased alkaline phosphatase activity in MG63 when Mg 
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doped hydroxyapatite cement (173) was added.  Furthermore, Mg2+ containing fluoridated 
hydroxyapatite (HA) coating also enhanced osteocalcin expression in MG63 cells (174).  These 
results support our findings of osteogenic marker enhancement by MgSO4 stimulation.   
Summarizing our qPCR array data, chondrogenesis of hBMSCs by MgSO4 stimulation was 
suggested because the upregulated genes included chondrocyte markers, such as COL3A1, 
COL10A1, COL11A1 (175), and COMP (176).  However, since the mRNA expression of collagen 
type II (COL2A1) was not significantly increased (data not shown), and mineral nodule formation 
was observed, we speculate that hBMSCs might have not differentiated to chondrocyte at this time 
point.  Moreover, it is reported that the COL2A1 expression is upregulated in human mesenchymal 
stem cells 10 - 21 days after cultured in chondrogenic condition (177), which indicates that 
hBMSCs in MgSO4 containing medium did not differentiate into chondrocyte due to lack of 
COL2A1 upregulation.  Moreover, upregulation of MMP2 suggests the enhancement of cell 
migration through ECM (178).    
Other genes upregulated by MgSO4 stimulation are IGF2 (insulin-like growth factor 2), 
GDF10 (growth differentiation factor 10), CTSK, and TWIST1.  IGF2 plays an important role in 
the growth of long bone, and upregulation of this gene may indicate that osteoblasts stimulated 
with Mg ion may promote bone growth by secreting IGF2.  GDF10 (also known as BMP-3b) is 
reported to be associated with osteogenic differentiation of primary osteogenic cells (179) and is 
also suggested to increase the osteogenic inducing activity of BMP-2 (180).  Cathepsin K is known 
as a osteoclast enzyme and is reported to accelerate trabecular bone turnover (181).  Twist1 is 
essential for osteoblast differentiation, but overexpression may inhibit osteogenesis (182). These 
changes may explain the enhanced osteogenesis of hBMSCs when stimulated with MgSO4. 
VEGFA expression did not change significantly in qPCR arrays (Fig 3) or confirmatory qPCR, 
 85 
including at earlier time points. On the other hand, some genes were downregulated (0.34 to 0.48 
fold) when assessed by qPCR. Integrin alpha 3 (ITGA3) expression is significantly decreased in 
the osteogenic medium.  ITGA3 is reported to be an important receptor for osteoblast to bind to 
Protein kinase C-binding protein NELL1 (osteoinductive protein) in ECM (183).  Decreased 
expression of ITGA3 may indicate enhanced migration of cells rather than adhesion, which could 
explain the enhanced bone regeneration in surrounding tissue of the Mg alloys in previous 
report(162). VCAM1, related to osteoclast activity, is upregulated via NFκB (184) and its 
expression was suppressed in the present study.  This may indicate the de-activation of osteoclastic 
activity.  
Since COL10A1 gene expression was significantly increased in both maintenance and 
osteogenic medium, the intracellular signaling pathway related to COL10A1 upregulation was 
further investigated in this study.  The Western blotting results indicate the different pathways of 
COL10A1 and VEGF expression under MgSO4 stimulation depending on the differentiation status 
of hBMSCs. In the maintenance medium, 10mM MgSO may have increased COL10A1 and VEGF 
levels by increasing the stability of HIF-2α protein. On the other hand, the production of HIF-2α 
was very low in the osteogenic medium; thus, the increase in PGC-1α expression in osteogenic 
medium may have contributed to increased transcription of COL10A1 and VEGF. 
Our data showing the mechanisms involved in Mg2+ signaling are schematically 
represented in (Figure 22).  HIF-1α and HIF-2α are transcription factors that are known to be 
stabilized in the cytosol under hypoxia (185) and in response to various metals (186, 187) activate 
genes including VEGF and glycolytic genes.  They are important transcription factors for bone 
development and regeneration (188, 189), as well as for inducing tissue remodeling (VEGF) and 
metabolic genes (e.g. glycolytic).  Potier, et. al. reported that hypoxia induced osteogenic 
 86 
differentiation and angiogenic factor expression in human mesenchymal stem cells (190), and 
Grayson, et. al. reported that hypoxia induced proliferation and ECM production in mesenchymal 
stem cells (191).  In fact, nickel and cobalt are known to enhance HIF expression (186), however, 
to the best of our knowledge, this is the first report of upregulation of HIFs by Mg2+.  Since Mg 
deficiency causes loss of response to hypoxia in paraganglion cells (192), it may be related to the 
regulation of reactive oxygen species (ROS) response by Mg2+ intake via Ca2+ channels.  PGC-1α 
is a HIF-independent transcriptional coactivator of VEGF (193) and is also known to regulate 
chondrogenesis in human mesenchymal stem cells (194).  However, the activation of PGC-1α by 
Mg2+ has not been reported.  PGC-1α expression is increased in response to Ca2+ activation of a 
calcineurin/calmodulin signaling complex (195).  Mg2+ also binds to calcineurin (196) and thus 
may act through a similar activation cascade to induce PGC-1α in hBMSC in osteogenic medium 
via activation of specific transcription factor (Figure 22). 
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Figure 22 Hypothetical scheme of different intracellular signaling cascades via Mg ion stimulation in 
hBMSCs.  We hypothesized that 10 mM MgSO4 cause an increase of concentration of intracellular Mg ion.  
And in undifferentiated BMSCs, HIFs are translocated into nucleus, and induce production of COL10A1 and 
VEGF.  On the other hand, in the osteoblastic BMSCs, the Mg ion activate transcription factor (TF), which 
activate PGC-1α production, and PGC-1α induce production of VEGF. 
 
To our best knowledge, this is the first report to show a possible Mg2+ stimulated 
intracellular signaling pathway in hBMSCs that may lead to the enhanced ECM mineralization 
observed in vitro and the enhanced bone regeneration observed in vivo (162).  Our findings, 
supported by those in the literature, suggest that an adequate concentration of Mg2+ should be 
maintained in healing bone tissue by adjusting the corrosion rate of Mg-based bone fixation 
devices.  Also, the excessive deposition of COL10A1 by Mg2+ could be applied to treating 
defective bone diseases such as Schmid type metaphyseal chondrodysplasia, osteogenesis 
imperfecta and osteoarthritis. 
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4.5 CONCLUSIONS 
Completion of this aim laid the groundwork for much of our research group’s ongoing 
investigation into the biological effects of degrading magnesium. The findings of this research will 
support our device development efforts as they add to the body of evidence suggesting degrading 
magnesium is biocompatible. However, equal investigation should be performed on the alloying 
elements of magnesium incorporated into future medical devices. One of the limitations to the 
approach we used in this aim is the wide net that must be cast to investigate any and all pathways 
affected by magnesium. This approach is neither time nor cost-effective in the long run and 
requires a more targeted approach. Observations of bone regeneration phenomenon surrounding 
magnesium in vivo can better shape hypotheses for more mechanistic investigation in vitro. For 
example, work by our group showing new bone formation above magnesium plates and screws 
and underlying the periosteum suggests that magnesium may be affecting genes and proteins 
expressed more predominantly in periosteal cells. More focused hypotheses will be necessary in 
the future to continue the generation of high-impact biological findings that can better inform 
device design. 
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5.0  SPECIFIC AIM 4: SYNTHESIZE AND PERFORM A PROOF-OF-CONCEPT IN 
VIVO IMPLANTATION OF A COMPLETE MAGNESIUM-BASED GUIDED BONE 
REGENERATION PLATFORM 
5.1 INTRODUCTION 
Following the successes of the Mg/PLGA bone graft substitute at regenerating bone in the socket 
preservation model, we aimed to develop new magnesium-based dental bone graft devices to 
produce a full guided bone regeneration platform. The two most obvious candidates for new 
devices were a barrier membrane and a magnesium micromesh on which a barrier membrane of a 
clinician’s choice could be placed. Additionally, we also planned to investigate the utility of a 
magnesium tenting screw serving as a bone grafting material, as is sometimes performed with 
titanium devices. These sorts of materials are most commonly used in more severe bone grafting 
settings which required development of a new surgical model. The goal of this study was not to 
comprehensively evaluate the magnesium/PLGA barrier membrane, magnesium micromesh and 
magnesium tenting screws in the same manner as the magnesium/PLGA bone graft substitutes. 
Rather, the goal was prototyping and manufacturing of these materials, followed by a proof-of-
concept implantation to confirm bone regeneration capabilities. We believed that a successful 
proof-of-concept bone regeneration study would provide the preliminary data to secure funding 
for a large scale in vivo study and strengthen the business case for a magnesium-based guided 
bone regeneration platform. This work was performed as part of a larger study on degradation 
control and functionalization of magnesium micromeshes. 
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5.1.1 Sixty Percent of Patients Require Bone Grafting prior to Dental Implant Placement 
Fifty percent of adults in the United States are missing at least one permanent tooth (excluding 
third molars) with 19% of adults aged 65 and over missing all permanent teeth (4). These teeth are 
commonly lost following trauma, radiotherapy or cancer resections of underlying bone, as well as 
poor dental hygiene resulting in tooth decay and periodontal disease. Nine percent of adults in the 
United States have some form of periodontitis which degrades the alveolar bone around teeth and 
can lead to loss of teeth in severe cases (4). Implant supported dental prostheses are becoming an 
increasingly prevalent method for restoring function and aesthetics following tooth loss. 
Unfortunately, chronic disease states frequently cause the bone resorption that underlies the 
original tooth loss and continues to occur following tooth loss. The lack of an adequate bony 
foundation (in terms of both bone quantity and quality) for implant placement results in half of 
patients requiring bone grafting to maximize the probability of implant survival (1). 
The extent of pre-implant bone grafting required is dependent on both the degree of bone 
resorption that took place prior to grafting, as well as patient-specific anatomical constraints. In 
cases where bone grafting is performed immediately following tooth extraction, a socket 
preservation approach can be pursued wherein bone grafting material is placed into the extracted 
tooth socket and left to regenerate (123, 124, 130, 131, 133, 142). However, in cases where there 
is a more significant lack of bone suitable for implant placement, vertical ridge augmentation is 
commonly pursued to increase alveolar bone height (19, 127, 197-199). In these more advanced 
cases of vertical ridge augmentation, a guided bone regeneration approach is commonly pursued 
(21, 22, 33, 83, 145, 197, 199). Guided bone regeneration, also referred to as guided tissue 
regeneration, is also commonly performed in the case of severe periodontal bone loss (20, 21, 25, 
33). 
 92 
5.1.2 Guided Bone Regeneration Approaches Combine Bone Grafting Material and an 
Occlusive Barrier Membrane to Promote Growth 
Guided bone regeneration approaches to vertical ridge augmentation involve the placement of 
bone grafting material in the region to be regenerated encompassed by an occlusive barrier 
membrane. The use of an occlusive barrier membrane serves to maintain the bone defect space, 
thus separating slowly-regenerating osteogenic cells from fast-migrating epithelial gingival cells. 
Commonly used non-resorbable barrier membranes are ePTFE, Ti-reinforced ePTFE and Ti mesh 
which provide excellent defect space maintenance, but require a removal surgery following bone 
regeneration (130, 197, 200). These non-degradable barrier membranes carry up to a 5% risk of 
membrane exposure (up to 44% risk in canine models) requiring early removal, thus jeopardizing 
full bone regeneration. Degradable barrier membranes, such as PLGA, allogenic dermal matrix or 
xenogenic collagen, reduce the exposure risk and eliminate the need for a removal surgery, but do 
not provide sufficient defect space preservation (25, 26, 29, 83) (Table 2). In cases where a 
degradable barrier membrane is used, the underlying bone graft provides a limited degree of 
mechanical support. 
Several animal studies and clinical studies have been performed to assess the utility of 
implanting titanium tenting screws or titanium dental implants as a means to tent the overlying 
barrier membrane and provide additional mechanical integrity to the healing defect site (201-210). 
While the use of these tenting devices was shown to encourage vertical ridge height regeneration, 
in the case of titanium screws, they must be removed during re-entry for implant placement. Thus, 
a guided bone regeneration therapy that provides mechanical strength sufficient for protecting the 
healing defect site while remaining fully degradable would be highly desirable. 
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5.1.3 Vertical Ridge Augmentation is Challenging to Obtain and Requires Long Healing 
Times 
As the volume of bone desired to be regenerated increases, more aggressive bone grafting 
techniques are required which result in longer healing times, increased probability of revision 
surgeries and decreasing likelihood of success. Patients requiring significant regeneration of 
vertical ridge height often require approximately a year of healing in order to regenerate up to only 
5mm of bone height (198). This is additional time spent with impeded masticatory function and, 
frequently, poor aesthetic appearance. More significant pre-existing bone loss, female gender, 
more advanced age, tobacco use and exposure to radiotherapy can contribute to longer bone 
regeneration times and lower likelihood of bone grafting success. While numerous bone grafting 
technologies and approaches exist to enhance the speed and probability of success of vertical ridge 
augmentation there remains substantial room for improvement.  
5.1.4 Vertical Ridge Augmentation Animal Models are Expensive and Time Consuming 
There are numerous animal models used for dental bone regeneration biomaterial evaluation 
reported in the literature. These dental bone regeneration studies are often cost and time intensive 
due to the lengthy healing periods required for large bone defect repairs. The most common 
animals used for these surgical models is the beagle or mongrel dog (200, 211-215) with some 
studies reported in rabbits (216, 217). The canine animal model permits the creation of defects on 
the scale of those observed in humans and allows the repair to be performed using the same scale 
materials and the same surgical techniques used in humans. The rabbit animal model typically 
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requires smaller defect creation and scaling down of biomaterials and repair procedures compared 
to those used in humans. 
Vertical ridge augmentation models are commonly pursued in the canine with both defect 
creation and surgical repair occurring in various manners. The most common model involves the 
extraction of bilateral mandibular premolars, often with extraction of molars as well, followed by 
8-12 weeks of healing time prior to a defect size standardization and repair surgery (211-215). In 
most cases, the maxillary premolars are either extracted or amputated at the crowns and capped to 
prevent trauma to the now edentulous mandible. This model most accurately represents the bone 
resorption processes that occur in humans and allows for highly standardized defects to be created. 
However, the initial tooth extraction surgery and additional 8-12 weeks of housing and animal care 
substantially increase the cost of the study. Several studies have further simulated the human 
disease process by creating periodontal disease prior to the tooth extraction and repair procedures 
(218, 219).  
Other groups have developed surgical models to perform repair procedures in the same 
surgery as defect creation (220, 221). While this approach reduces the cost and time associated 
with the experiment, defect standardization is often limited by anatomical differences between 
animals and between different defect sites within an animal. Common among all of these 
approaches though are the experimental approaches to assessing bone regeneration following the 
explantation of defects. All studies performed radiographic or microCT analyses of common bone 
measurements to provide clinically relevant outcome measures. Most also perform histological, 
and occasionally histomorphometric, analyses to provide more insight into device/treatment 
biocompatibility and biological process surrounding the bone regeneration. The choice of each 
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animal model, surgical model and endpoint assessments is entirely dependent on the aims of each 
individual study. 
5.1.5 Degradable Magnesium Devices have been shown to Enhance Bone Formation 
Metallic magnesium has recently emerged as an attractive material for developing orthopedic and 
craniomaxillofacial devices. Magnesium exhibits strength and density similar to that of bone while 
remaining fully degradable when exposed to body fluid. Thus, magnesium and magnesium alloys 
have been manufactured into plates, screws, pins and rods and exhibited excellent biocompatibility 
when implanted in multiple in vivo models (50, 51, 54, 58, 59, 61, 62, 64, 106, 222). Witte, et. al., 
implanted magnesium alloy rods and PLA rods into rabbit femora and monitored the osteogenic 
response as the rods degraded. Significantly more bone was regenerated surround the degrading 
magnesium rods compared to PLA controls (59). Additionally, previous work by our group 
demonstrated that magnesium plates and screws successfully fixated a rabbit ulnae fracture 
throughout a 16wk healing duration. In addition to fixating the fracture, we observed bone 
formation above and around the fixation plates and screws were bone had not previously existed 
(76, 148). This led us to investigate potential applications for magnesium’s osteogenic properties 
in a dental defect. 
 As discussed in Brown, et. al., our group synthesized novel a porous Mg/PLGA composite 
bone graft scaffold. This composite enabled us to harness the versatility of PLGA and the 
osteogenic enhancement imparted by degrading magnesium. Our characterization of these 
Mg/PLGA scaffolds showed that they increased proliferation of bone marrow stromal cells in vitro 
and increased bone height regenerated in a canine socket preservation model (223). These findings 
from our group and others in the field suggest that metallic magnesium holds promise for not only 
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the manufacturing of degradable devices, but for imparting enhanced osteogenic activity around 
regenerating bone defects. 
5.1.6 Could Magnesium’s Osteoconductive Capabilities be Harnessed in a Novel Guided 
Bone Regeneration Therapy? 
We hypothesized that metallic magnesium could be incorporated into devices for two GBR 
therapeutic approaches and that the magnesium-based GBR approach would show enhanced bone 
volume and bone height regenerated compared to titanium and allograft standard-of-care. To our 
knowledge, this is the first investigation of the manufacture and implantation of magnesium GBR 
devices.  
Our objectives were to first modify a standard canine vertical ridge saddle defect model to 
allow for faster and less resource intensive evaluation of GBR devices. Then, we aimed to show 
that magnesium screws, micromeshes and Mg/PLGA membranes could be successfully 
manufactured and implanted in vivo using standard clinical techniques. Using the magnesium 
screws as tenting devices covered by Mg/PLGA barrier membranes or micromeshes, we aimed to 
evaluate the osteogenic response upon implantation in a canine vertical ridge augmentation model. 
Finally, evaluation of the explanted canine mandibles using microCT and histological techniques 
was performed to answer questions regarding bone regeneration, device degradation and 
biocompatibility to better guide device design and manufacturing as we prepare for a large scale 
in vivo study.  
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5.2 MATERIALS AND METHODS 
5.2.1 GBR Materials Synthesized and Obtained for Implantation 
Three types of magnesium GBR devices were manufactured for implantation in the vertical ridge 
augmentation model using commercially available stock material and customized manufacturing 
methods. These novel materials were compared to commercially available titanium micromesh 
and fixation screws with human allograft as described in detail below (Table 6). 
 
Table 6 Experimental and control GBR groups and their associated materials. 
 
5.2.1.1 Synthesis of Magnesium / PLGA Barrier Membranes 
Magnesium/PLGA barrier membranes were synthesized using a three layer solvent casting 
approach (224, 225). This approach followed a similar strategy and was aimed to provide a similar 
device to the Mg/PLGA bone graft scaffolds described in Specific Aim 1 of this thesis (223). 
PLGA (50:50, Mw 7,000-17,000, Sigma Aldrich) was dissolved into dichloromethane (DCM, 
Sigma Aldrich) at a concentration of 20% (w/v) and briefly sonicated at room temperature. 600ul 
of the PLGA/DCM mixture was then added to a custom Teflon mold (30mm x 20mm x 1mm) at 
4degC and the DCM was allowed to evaporate for 2h. A second layer was synthesized by adding 
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40mg of pure metallic magnesium particles (>99% purity, <300um particle size, Sigma Aldrich, 
St. Louis, MO) into the PLGA/DCM mixture and then pipetting the 600ul Mg/PLGA/DCM 
mixture on top of the 1st PLGA/DCM layer. An additional 2h was allowed for DCM evaporation 
at 4degC. Finally, a 3rd layer of PLGA was added to the mold in the same manner as layer 1. The 
final Mg/PLGA membrane was left at 4degC overnight to allow controlled DCM evaporation, thus 
minimizing bubble formation. The membranes were then removed from the molds and left in a 
fume hood to continue to dry for 72h (Figure 23A). 
 
Figure 23 Experimental magnesium materials evaluated in a canine vertical ridge augmentation 
model. A) Mg/PLGA barrier membrane synthesized using solvent casting. B) Magnesium micromesh 
manufactured using laser cutting. C) Magnesium screws for periosteal tenting and mesh fixation 
manufacturing using CNC machining. 
 
5.2.1.2 Manufacturing of Magnesium Micromeshes 
Magnesium meshes were manufactured from commercially available magnesium foil stock 
subjected to laser cutting to obtain a customized design. Custom mesh geometries were designed 
in SOLIDWORKS (Waltham, MA) to emulate commercially available titanium micromeshes, 
provide geometric consistency with defects created in the in vivo study and optimize screw 
fixation. Magnesium foil (99.9% purity, 0.5mm thickness, Goodfellow, Coraopolis, PA) was laser 
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cut to the specified designs using a 150W laser (Kern HSE, Kern Laser Systems, Wadena, MN) at 
the Swanson Center for Product Innovation at the University of Pittsburgh. Magnesium meshes 
were deburred, polished with 1200 grit silicon carbide abrasive discs and etched in a glycerol, 
nitric acid, acetic acid solution for 60 seconds to provide uniform corrosion layers (Figure 23B). 
Meshes were then heat treated at 200degC for 1h in an argon furnace to allow for strain relief. 
5.2.1.3 Manufacturing of Magnesium Tenting and Mesh Fixation Screws 
Magnesium screws were manufactured from commercially available magnesium rod stock 
subjected to computerized numerical control machining. Screw geometries were designed in 
SOLIDWORKS to emulate commercially available titanium microfixation screws. The same 
design was used for the tenting and mesh fixation screws. Magnesium rods (99.9% purity, 3.2mm 
diameter, Goodfellow) were machined at the Swanson Center for Product Innovation at the 
University of Pittsburgh and then alkyl treated to provide uniform corrosion layers as discussed 
above (Figure 23C). Screws were then heat treated at 200degC for 1h in an argon furnace to allow 
for strain relief. 
5.2.1.4 Procurement of Clinical Standard-of-Care Materials 
Human allograft bone putty (RegenerOss Power Putty, Biomet 3i, Palm Beach Gardens, FL) was 
used as the clinical standard-of-care grafting material for this study. Titanium micromesh (0.2mm 
thickness, Stryker, Kalamzaoo, MI) was used as the clinical standard-of-care barrier material and 
was secured with titanium microfixation screws (1.2mm diameter, 3mm length, Stryker). 
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5.2.2 Surgical Implantation, Animal Care and Euthanasia 
5.2.2.1 Surgical Study Design and Preparation 
Magnesium meshes and screws, along with the Mg/PLGA barrier membranes were sterilized using 
gamma irradiation with a dose of 20,000Gy at a dose rate of 23.5Gy/min (Mark I 68, JL Shepherd 
and Associates, San Fernando, CA). Titanium micromesh, fixation screws and surgical tools were 
sterilized using a steam autoclave. 
The in vivo study protocol was approved by the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. Defects were created and repairs were performed in a 
split mouth design in the left or right mandibular second (P2) or fourth (P4) premolar region in 
three female beagle dogs aged 12 months old (Marshall BioResources USA). 
5.2.2.2 Surgical Procedure 
Dogs were sedated with acepromazine and placed in ventral recumbency under isofluorane 
anesthesia. The skin surrounding the muzzle was prepped with betadine and sterile techniques 
were used throughout the surgery. The gingival tissue and underlying periosteum were released 
following the creation of an incision from behind the first molar (M1) to in front of the second 
premolar. The second (P2) and fourth (P4) premolars were then extracted (Figure 24A). A 
reciprocating saw was then used to remove the remaining intercrestal bone and create a normalized 
defect 10mm in mesiodistal length, 8mm in height and the full lingual/buccal thickness (Figure 
24B). For the magnesium experimental groups, pilot holes were predrilled into the remaining 
alveolar bone and 2 tenting screws were placed (Figure 24C). The tenting screws were then 
covered with either a magnesium mesh tucked into the lingual gingival flap and secured on the 
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buccal alveolar bone with 2 magnesium screws, or were covered with a Mg/PLGA membrane that 
was sutured into place with 4-0 Vicryl sutures (Figure 24D).  
 
Figure 24 Proof of concept implantation of Mg/PLGA barrier membranes and Mg meshes with Mg 
tenting screws was performed using a canine vertical ridge augmentation surgical model. A) The second and 
fourth premolars were extracted and B) the standardized 10mm wide, full-thickness bone defect was created. 
For the magnesium experimental groups, C) 2 tenting screws were placed and D) were covered with either a 
magnesium mesh or Mg/PLGA membrane. 
 
5.2.2.3 Post-Surgical Animal Care and Endpoints 
Dogs received 0.2mg/kg meloxicam once a day for analgesia and 20mg/kg meloxicam twice a day 
for 3d post-op for antibacterial therapies. Dogs were allowed standard enrichment, but remained 
on a soft diet for the entire study period. Euthanasia was performed under sedation with 1ml/4.5kg 
beuthanasia 12 weeks post-surgical implantation. Photographs were taken of the healed defect sites 
to assess soft tissue healing. Left and right mandibular segments were explanted and trimmed to 
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separate the two defect sites on each side. The surrounding soft tissue was dissected and the 
samples were fixed in formalin for 3d.  
5.2.3 Micro-CT Analysis 
Prior to implantation, all magnesium meshes and screws were scanned in an ex vivo uCT system 
(Skyscan 1172, Bruker-Skyscan, Belgium) at 6um voxel size, 79kVp source voltage, 125uA 
source current 800ms exposure, 10 frames averaged per view and 360 degrees angular range of 
scan. Each device was individually tracked to enable 1:1 comparisons of device volume before 
and after implantation to provide highly specific degradation measurements. Following pre-
implantation microCTs, the raw scans were reconstructed using Recon, reoriented using 
Dataviewer (Skyscan) and analyzed using CTAn as described below. 
Following explantation of mandibular section and prior to scanning, the enamel on the P3 
crown was ground off and the 1st premolar and 1st molar crowns were removed to reduce beam 
hardening artifact. Individual defects were then separated by trimming through the third premolar. 
The samples were scanned and reconstructed as described above. The post-explantation scans were 
analyzed using CTAn (Skyscan) following truncation to separate each defect into an individual 
scan. Post-implant magnesium device volume, defect bone height and defect bone volume were 
then calculated for each site.  
5.2.3.1 Magnesium Device Degradation Measurement 
Truncated pre-implantation microCT reconstructions were segmented and binarsed to allow 
calculation of device volume for each individual magnesium screw and mesh. For post-
explantation device volume measurement, reconstructions were reoriented and output as new scans 
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using DataViewer such that each magnesium fixation screws or the magnesium tenting screws was 
oriented axially. The screws were manually segmented using circular regions of interest and then 
binarized using thresholds to capture only the non-corroded volume of the magnesium screws 
(Figure 25). Device degradation was calculated as the percentage change in device volume from 
pre-implantation to post-explantation (76). 
 
Figure 25 Overview of post-explantation magnesium screw volume determination workflow. Following 
microCT scanning, reconstruction and truncation, scans were A) reoriented to provide an axial view of each 
screw. B) Each screw was then defined with a circular region of interest across the full length of the screw and 
subjected to binarisation to yield C) the non-corroded screw volume absent of surrounding bone volume of 
similar density. 
 
5.2.3.2 Defect Bone Height Measurements 
Bone height in each defect area was computed by first connecting the plane between the alveolar 
crests mesial and distal to the defect (intercrestal plane) using ImageJ (NIH, Bethesda, MD) (223, 
226). Then, the distance between the intercrestal plane and the bone height in the middle 
(mesiodistal axis) of the defect was measured from the center of the socket defect. Bone height 
measurements were averaged from 3 different sections for each defect (Figure 26).  
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Figure 26 Schematic of bone height determination for a representative magnesium tenting screw 
sample. Three microCT cross-section images from each defect were imported into ImageJ. A line was drawn 
between the intercrestal alveolar bone borders next to the two teeth mesial and lateral to the defect (yellow 
dashed line). Next, a line was drawn from the intercrestal alveolar bone line to the mid-defect bone height 
(green dash line) and that height was measured and output from ImageJ and averaged amongst the three 
images from each sample. 
 
5.2.3.3 Defect Bone Volume Measurements 
Defect bone volume was calculated by orienting the scans as buccolingual sections. The 
boundaries of the remaining mesial and distal roots of the teeth on either side of the defect were 
set as the bounds of the original defect volume to be analyzed across the full buccolingual 
thickness. Regenerated bone volume calculation was performed using binarisation based on the 
defined thresholds for scan sections across the entire defect thickness with optimization to exclude 
remaining magnesium hardware. This calculated bone volume in the defect was then divided by 
the regenerated total volume of tissue space encapsulated by the outermost bone tissue to compute 
%BV/TV (Figure 27). 
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Figure 27 Overview of bone volume determination for a representative magnesium tenting screw 
sample. A) Cross sections of the microCT scans were taken and B) regions of interests were defined with the 
mesial and lateral teeth and the full buccal and lingual bone volume defining the borders to the distal root of 
the two tooth roots. C) The regions of interests were then binarised to threshold both the soft tissue and 
magnesium devices out of the final bone volume determinations. 
 
5.2.4 Histology 
Following micro-CT, un-decalcified samples were dehydrated and embedded in Osteo Bed Plus 
Bone Embedding solution (Polysciences, Warrington, PA) according to manufacturer’s protocol. 
Following polymerization, plastic blocks were trimmed using a band saw and low speed diamond 
saw. Serial sections were then obtained at 5um thickness using a microtome with tungsten-carbide 
blade and tape transfer technique (Leica RM2255, Leica, Buffalo Grove, IL). 
5.2.4.1 Goldner’s Trichrome Staining 
Goldner’s Trichrome staining was performed to examine general tissue morphology and 
composition of the samples. Staining solutions were obtained from Electron Microscopy Sciences. 
 106 
Sections were deacrylated in xylene and methoxyethylacetate, cleared with a descending ethanol 
series and then held in distilled water. Sections were incubated with hematoxylin, Ponceau-acid, 
Orange G-Phospho and Light Green then dehydrated with and ascending series of ethanol prior to 
mounting with Eurapal mounting medium.  
5.2.4.2 Microscopy 
Brightfield microscopy was performed with a Nikon TE 2000 microscope (Melville, NY) equipped 
with a Nikon DS-Fi1 camera. Micrographs were captured and background illumination and white 
balance corrections were performed using Nikon NIS Elements. 
5.3 RESULTS 
5.3.1 Magnesium Devices were Successfully Implanted and fit into Standard Clinical 
Workflow 
The Mg/PLGA barrier membrane, Mg micromesh and Mg tenting screws fit into the standard 
clinical workflow throughout the implantation surgeries. The Mg tenting screws were placed into 
the remaining alveolar bone following pre-drilling with one failure of a tenting screw, at the runout, 
during driving. The dimensions of the screw resulted in approximately 3mm of the device 
remaining above the defect border. The Mg/PLGA barrier membrane could be easily trimmed with 
scissors, was pliable enough to be custom fit to individual defect borders and retained sutures 
during implantation and closure. The magnesium micromesh could be easily trimmed with 
scissors, if necessary due to anatomical constraints, and was pliable enough to be custom fit to 
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individual defect borders. There was no noticeable micromotion following mesh fixation with the 
Mg screws. Implantation of devices allowed for full, tension-free closure of the overlying 
periosteum and gingival tissue. 
5.3.2 Magnesium GBR Devices caused no Detectable Adverse Events during 12 week 
Study Period 
Following 12wks of healing post-implantation surgery, no adverse events related to the magnesium 
device implantation were detected. However, both titanium meshes became increasingly re-
exposed throughout the duration of the study; however, no intervention was made. No significant 
gas bubble formation was noted on gross examination surrounding the magnesium devices as has 
been reported in other studies. While the titanium meshes became re-exposed, the progression of 
soft tissue healing surrounding the magnesium-repaired defect sites was unremarkable (Figure 28). 
There were no signs of infection or dehiscence surrounding the magnesium-repaired defect sites. 
 
Figure 28. Defect sites 12wk following repair with A) Mg tenting screws and micromesh between M1 
and P3, Mg tenting screws with Mg/PLGA barrier membrane between P3 and P1 and B) titanium micromesh 
with human allograft between P3 and P1. 
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5.3.3 Magnesium Screw Degradation Successfully Measured 
All twelve magnesium screws placed in this study were subjected to pre-implantation microCT 
scanning. Pre-implantation screw volume was 8.4±0.2mm3. Following the 12wk study period and 
explantation, six screws placed in the tenting position were found to have average screw volume 
of 6.3 ± 0.5mm3. One tenting screw broke during implantation leaving only the shaft placed in the 
tenting positions. Another tenting screw volume could not be determined in the post-explantation 
scans due to a microCT scanning technical error. Four screws placed in the mesh fixation position 
were found to have average screw volume of 5.0 ± 0.7mm3. These pre-implant and post-
explantation screw volumes translated to 26 ± 5.3% and 41 ± 7.6% device degradation for the 
tenting and fixation screws, respectively (Figure 29). 
Figure 29 Screw volumes were computed using microCT analysis both before implantation and after 
implantation. Screws placed as tenting screws (n=6) had 74% volume remaining while mesh fixation screws 
(n=4) had 59% volume remaining after a 12wk implantation. 
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5.3.4 Magnesium GBR Groups Exhibited Increased Bone Height Relative to Titanium 
Mesh and Allograft groups 
Bone height was successfully measured for all six defect sites included in this study. Intraobserver 
reliability of measurements on a single slice was found to be 6.6% RSD while intraobserver 
reliability of 3 full measurements on one sample was found to be 11.2% RSD. Defect sites 
receiving Mg tenting screws with Mg/PLGA barrier membranes had bone height 1.5 ± 0.4mm 
below the intercrestal plane. Mg tenting screws + Mg mesh defects had bone height 2.4 ± 0.1mm 
below intercrestal plane while human allograft + Ti micromesh defects had bone height 2.6 ± 
0.3mm below intercrestal plane (Figure 30).  
Figure 30 Representative bone heights of a A) Mg tenting screw + Mg/PLGA membrane defect, B) Mg 
tenting screw + Mg mesh defect, C) human allograft + titanium mesh defect. D) Bone heights were averaged 
from 2 samples for each group. 
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5.3.5 Bone Regeneration in Defect Area was Calculated using microCT 
Qualitative analysis of the microCTs revealed differences in regenerated bone morphology and 
device/bone integration within the areas of the defect (Figure 31A-C). Bone was found to be in 
contact with Mg tenting (*) and fixation screws throughout some areas of interest, while areas of 
poor bone contact and possible bone resorption were noted in others. Additionally, possible gas 
bubbles were noted throughout the tissue surrounding the magnesium devices (^). Mg tenting 
screw + Mg/PLGA membrane samples exhibited bone thickness regeneration across the full 
buccolingual axis (Figure 31A). Mg tenting screw + Mg mesh samples exhibited greater  
buccolingual bone thickness regeneration due to bone overgrowth around the Mg mesh () on the 
lingual side of the defect (Figure 31B). Human allograft + Ti mesh (%) samples showed limited 
buccolingual thickness regeneration with a significant amount of allograft (white arrows) 
remaining at 12 weeks (Figure 31C). 
Regenerated defect tissue volumes were measured for the Mg tenting screw + Mg/PLGA 
membrane (n=2), Mg tenting screw + Mg mesh (n=2) and human allograft + Ti mesh groups (n=2) 
as 198 ± 37, 329 ± 216 and 142 ± 12mm3, respectively (Figure 31D). Regenerated defect bone 
volumes within the regenerated defect tissue volumes were determined through thresholding to be 
94 ± 16, 85 ± 28 and 82 ± 3mm3 for the Mg tenting screw + Mg/PLGA membrane, Mg tenting 
screw + Mg mesh and human allograft + Ti mesh groups, respectively (Figure 31D). These 
measurements were used to calculate regenerated defect bone volume / tissue volume percent as 
47 ± 0.8, 29 ± 11 and 56 ± 3% for Mg tenting screw + Mg/PLGA membrane, Mg tenting screw + 
Mg mesh and human allograft + Ti mesh groups, respectively (Figure 31). 
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Figure 31 A-C) Regenerated defect tissue volume was identified as the region of interest (dashed white 
lines) for each sample. The regenerated defect tissue volume was measured from the apical root level to the 
highest level of intercrestal bone regeneration through the full buccolingual thickness. Also identified are Mg 
tenting screws (*), Mg mesh (), potential gas bubbles (^), titanium mesh (%) and remaining human allograft 
(white arrow) D) The regenerated bone volume was identified through thresholding of the region of interest to 
exclude soft tissue and magnesium devices and E) regenerated defect tissue volume / regenerated defect bone 
volume was calculated.  
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5.3.6 Magnesium GBR Groups Exhibited Good Biocompatibility when Examined with 
Histological Methods 
Goldner’s trichrome staining of full section explants revealed several differences between our 
experimental groups beyond microCT findings. Mg tenting screw + Mg/PLGA membrane samples 
showed new bone formation above the screws with active osteoid still visible. Interestingly, in 
some areas surrounding the screws no device remnants, bone or soft tissue was visible (Figure 
32A,C). Similar results were observed around the Mg tenting screws covered by the Mg 
micromesh. However, areas around the mesh fixation screws where there previously was bone 
showed empty spaces with neither active bone resorption nor soft tissue (Figure 32B,E). Finally, 
histological analysis of the human allograft + Ti micromesh samples revealed active bone 
resorption in the defect area with substantial accumulations of inflammatory cells. The Ti mesh 
fixation screw that had been placed in sound alveolar bone was now surrounded entirely in 
nonmineralized tissue (Figure 32C,F).  
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Figure 32 Goldner’s trichrome staining of full section explants of A) Mg tenting screw + Mg/PLGA 
membrane, B) Mg tenting screw + Mg micromesh and C) human allograft + Ti micromesh samples. Higher 
magnification images were taken within the defect area showing D-E) new bone with active osteoid above Mg 
tenting screws in both Mg/PLGA membrane and Mg micromesh samples and F) bone resorption processes 
around human allograft + Ti micromesh samples.  
5.4 DISCUSSION 
The primary goal of this study was to evaluate the usability and biocompatibility of a Mg tenting 
screw, Mg/PLGA barrier membrane and Mg micromesh in a proof-of-concept canine vertical ridge 
augmentation model. We hypothesized that the novel devices would show enhanced bone volume 
and bone height regenerated compared to standard-of-care controls. We modified a canine vertical 
ridge saddle defect surgical model to allow defect creation and repair in a single surgery to reduce 
cost and experimental time. The Mg tenting screw, Mg/PLGA barrier membrane and Mg 
micromesh all fit into the standard clinical workflow and were successfully implanted with only 
one failure of a tenting screw during driving. The defect sites receiving Mg-based repairs exhibited 
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regeneration of bone, as measured with microCT, within the defects and provided better restoration 
of bone than the human allograft and Ti micromesh defect sites. Finally, histological analyses 
revealed good biocompatibility for the defect sites receiving Mg-based repairs, while the sites 
receiving human allograft and Ti micromesh exhibited substantial inflammation due to mesh re-
exposure. Overall, we believe these findings support further investigation of the Mg tenting screw, 
Mg/PLGA barrier membrane and Mg micromesh in a larger scale and experimentally refined 
animal study. 
The novel magnesium bone grafting devices were successfully synthesized using 
laboratory-scale manufacturing methods. The Mg tenting screws were manufactured to a high 
degree of precision (2.5% relative standard deviation of screw volume) and successfully implanted 
with 1 of 12 screws failing during driving. Magnesium alloys could be investigated as alternative 
materials for these tenting screws to improve mechanical properties and reduce failure during 
driving (51, 58, 159, 222). However, substitution of an alloy system in place of pure Mg would 
also alter the degradation rate and potentially the biocompatibility of our devices, requiring 
additional testing. The Mg/PLGA barrier membranes were successfully synthesized, but will 
require substantial refinement prior to clinical use. The multi-layer solvent casting method 
provided sub-optimal homogeneity with respect to Mg particle distribution throughout the 
membrane. Going forward, advancement of the Mg/PLGA barrier membrane will require new 
manufacturing methods to improve homogeneity and eliminate the use of chlorinated solvents 
which could cause toxicity issues. The Mg micromeshes were manufactured using similar process 
to those used for larger-scale medical mesh fabrication and would require the least refinement prior 
to clinical use. However, design work will be required to create a geometric pattern amenable to 
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trimming prior to use to provide defect-specific devices, rather than the one-size-fits-all approach 
we used for this study. 
Our research group successfully performed an alveolar ridge saddle defect creation and 
repair procedure in a single surgery; however, further refinement of this surgical model is required 
prior to a larger scale study. We successfully validated the implantation procedures for our devices 
and found a lack of adverse events associated with their use. However, our standard-of-care control 
groups (human allograft + Ti micromesh) exhibited mesh re-exposure which likely led to 
subsequent infection and bone resorption / lack of regeneration. While exposure of meshes and 
membranes is observed clinically, it prevents appropriate comparisons between our Mg therapies 
and such control groups (130, 200). More care could be taken to remove sharp edges on the Ti 
mesh which may lead to soft tissue injury. Additionally, more screws could be used to provide 
additional fixation and prevent micromotion which could lead to bone resorption and mesh 
migration. Another limitation of this surgical model was the difficulty to standardize defect 
geometries due to the presence of the third premolar and anatomical difference between the bony 
defect site previously holding the second and fourth premolars. This could be improved by 
removing all premolars and allowing a healing period similar to other surgical models; however, 
differences in buccolingual thickness and alveolar bone height are likely to remain as confounding 
factors in geometrical defect standardization (200, 211-215). 
Device degradation was successfully measured for the magnesium tenting screws and mesh 
fixation screws. There was a difference in degradation between the two different screw positions 
(26% volume lost for tenting screws vs. 41% volume lost for fixation screws). This may have been 
due to differences in the microenvironments the screws were placed in or could have been related 
to differences in device loading patterns. These data compare well with results published by Chaya, 
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et. al., which measured approximately 30% volume loss of pure Mg screws in a rabbit ulnae 
fracture model following 8 weeks of implantation (76).  Henderson, et. al. measured volume loss 
of 70% following 12 weeks of implantation of pure Mg screws in a mandibular implantation model 
(222). These differences in degradation rates are also likely heavily dependent on the tissue 
environments where the magnesium devices are implanted. Magnesium micromesh degradation 
measurements could not be performed using standard microCT methodologies due to the complex 
and non-continuous geometry of the device. Alternative methods of measurement are currently 
under investigation. 
Bone height measurements were performed to identify the intercrestal bone height deficit 
in the defect region as this is a common clinical measurement. The Mg tenting screw + Mg/PLGA 
barrier membrane group was found to have regenerated the most bone height with Mg tenting 
screw + Mg micromesh and human allograft + Ti micromesh groups having similar bone height 
regenerated. New bone was identified superior to the Mg tenting screws which is similar to 
observations around other implanted magnesium screws (76, 148). Bone height measurements 
were limited by the lack of definition of the original defect boundaries. The measurements are 
currently performed using the remaining intercrestal alveolar bone as the landmark for 
standardization. However, this intercrestal alveolar bone at the borders of the defect could resorb 
or regenerate as well, thus skewing bone height measurements. The more relevant measurement 
would be bone height regenerated, i.e. the height of new bone as measured from the apical defect 
border. In future studies we will pursue methods of defining the lower defect border through 
implantation of radiopaque markers. 
Bone volume regeneration in the defect area was calculated and revealed a number of 
differences between the three experimental groups other than those obvious through bone height 
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measurements alone. Mg tenting screw + Mg micromesh samples had a larger defect tissue volume 
regenerated due to increased buccolingual thickness regenerated and bone overgrowth around the 
micromesh. This bone overgrowth, where bone had not previously been found, has been reported 
by others (76, 148). However, because this overgrowth left large areas of soft tissue encapsulated 
by bone, this group’s regenerated bone volume was not larger than the other two experimental 
groups. Human allograft + titanium micromesh samples had a lower regenerated total volume due 
to a lower bone height and buccolingual width regenerated. No difference was measured in 
regenerated bone volume among the three groups surprisingly. This could be due to differences in 
anatomy at the defect sites and difficulty standardizing defect size, as previously discussed. 
Improved methods of defect border identification will be required for higher fidelity analysis of 
bone volume regenerated. Additional work is planned to better define the defect borders and newly 
regenerated bone through the use of toluidine blue staining and polarized light microscopy (227). 
A histomorphometric approach to determining bone volume regeneration may yield stronger 
support of bone regeneration enhancement. Potential gas bubbles were identified around the Mg 
devices which may have prevented additional bone regeneration and osseointegration of the Mg 
tenting screws throughout their full length. Immunohistochemical methods will be performed in 
the future to identify possible mechanisms underlying the variability in device/bone integration. 
Histological assessment confirmed the overall positive osteogenic response to the 
implanted magnesium devices. New bone was identified surrounding the Mg micromesh and 
superior to the Mg tenting screws. Active osteoid was identified throughout these magnesium 
samples as well, suggesting that bone regeneration and remodeling was ongoing. Significant 
inflammatory tissue was visible throughout the human allograft + titanium micromesh samples 
which likely severely comprised the bone regeneration process. Bone resorption surrounding the 
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titanium mesh fixation screws was also noted. Further work is planned on evaluating the response 
to the implanted devices through tartrate resistant acid phosphatase (TRAP) staining. This 
procedure will enable comparison of bone formation vs. resorption around the degrading devices 
and could shed light on the mechanisms of osseointegration variability observed. Chloroacetate 
esterase staining will also be performed to assess inflammation surrounding the implanted devices. 
This comprehensive histological assessment will strengthen the body of evidence regarding 
magnesium’s biocompatibility. 
5.5 CONCLUSIONS 
Completion of this aim demonstrated that Mg-based GBR devices could be successfully 
manufactured and implanted. Our primary objective was to perform this study to better guide 
device design, manufacturing and evaluation going forward. This objective was met. The Mg 
tenting screw concept, as well as the Mg/PLGA barrier membrane and Mg micromesh performed 
in a manner that deserves further development and evaluation. Unfortunately, endpoint 
assessments revealed several shortcomings in our proof-of-concept surgical model that impeded 
our ability to draw less descriptive and more quantitative conclusions from our data. Research on 
regulatory processes for these GBR devices revealed that a vertical ridge augmentation model is 
the most likely surgical model to be performed for approval or clearance of these devices. Thus, 
future efforts will be directed towards improving this surgical model for further use by our research 
group. Our finding of new bone growth around degrading magnesium devices where it did not 
previously exist supports our research group’s consistent findings of enhanced osteoconductivity 
around magnesium. An improved vertical ridge augmentation surgical model could allow more 
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mechanistic biological investigations, using immunohistochemical techniques, into the potential 
role of the periosteum in this phenomenon. This study was successful in confirming the utility of 
these novel devices, but much work remains to validate their clinical and commercial potential and 
understand the observed variability in device osseointegration and bone regeneration. 
5.6 ACKNOWLEDGEMENTS 
The contributions of Avinash Patil and Elia Beniash surrounding study design, magnesium mesh 
polishing and alkyl treatment steps are greatly appreciated. J. Andrew Holmes of the Swanson 
Center for Product Innovation and Haoyuan Mu and Brian Webler of the Department of Materials 
Science at Carnegie Mellon University assisted with magnesium mesh and screw manufacturing 
and processing. Michael Epperly of the University of Pittsburgh Cancer Institute kindly provided 
gamma sterilization of our implanted devices. Andrew Glowacki and Steven Little provided 
assistance with Mg/PLGA membrane synthesis. The University of Pittsburgh’s Division of Live 
Animal Research and Surgical Research provided husbandry care and excellent surgical support 
services. Christian Moore, James Omlie, Herbert Ray Jr. and Qahtan Al-Qahtani performed the 
surgeries with the guidance of BJ Costello and Samer Zaky. Kostas Verdelis and Rong Chong 
were instrumental in obtaining and processing microCT scans. Nicole Myers and Michele Mulkeen 
are greatly acknowledged for their work on histological assessments. Finally, the funding support 
of the Center for Medical Innovation, Innovation Institute, Commonwealth of Pennsylvania, 
McGowan Institute for Regenerative Medicine, Innovation Works and the Revolutionizing 
Metallic Biomaterials Engineering Research Center is greatly appreciated. 
 120 
6.0  SUMMARY OF THESIS WORK 
The overall goal of this thesis was to design, manufacture and evaluate Mg-based guided bone 
regeneration devices and to expand our knowledge of the biological effects of these Mg devices, 
(both directly and indirectly) on osteogenesis, angiogenesis and inflammatory processes. Our 
primary hypothesis was that characterization of a magnesium-based bone grafting platform would 
demonstrate enhanced osteogenicity over currently used materials. We designed four studies to 
test this overall hypothesis and work towards meeting our primary objective.  
First, we successfully synthesized and performed material characterizations on a 
Mg/PLGA composite bone graft substitute. We confirmed our hypotheses that these Mg/PLGA 
bone graft scaffolds could ameliorate the acidic degradation profile observed in PLGA only 
devices, release magnesium throughout their degradation, increase compressive strength of PLGA 
only scaffolds and increase cell proliferation in vitro. More in-depth evaluation of the mechanisms 
of the pH buffering effect could enable us to pursue new applications for this technology in drug 
or biologic delivery. Additionally, various other polymer systems could be developed for other 
applications, such as soft tissue healing. 
Next, we evaluated the bone regeneration capabilities of these Mg/PLGA composite bone 
graft substitutes in a clinically relevant socket preservation model. We confirmed our hypotheses 
that the Mg/PLGA scaffolds could be successfully implanted in the socket defects and would prove 
safe and effective at regenerating bone in a socket preservation model. Both the bone height and 
bone volume of the defects receiving Mg/PLGA scaffolds exhibited increases compared to defects 
left empty. While this experiment confirmed the ability of the scaffold to support bone regeneration 
in vivo, little is known about the mechanisms why. Future work is planned to examine the 
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biological response to implantation of these materials at shorter timepoints. Additionally, 
immunohistochemical evaluation of the interface between the devices and the periosteum could 
provide insight into magnesium’s osteogenesis enhancement. 
We expanded our knowledge on the biological mechanisms affected by magnesium by 
designing an in vitro study to measure osteogenesis related gene expression and protein production 
changes following exposure to increased concentrations of magnesium ion. We determined that 
10mM MgSO4 added to tissue culture medium increased hBMSC proliferation, matrix 
mineralization and expression of osteogenic genes and proteins. A more scalable approach is 
needed for future investigations of magnesium’s effects on biological mechanisms. This can likely 
be done by leveraging already obtained in vivo explants for use in immunohistochemical 
examinations around possible regions of initial increased bone regeneration (periosteum, bone 
marrow, perivascular) and then combining those data with more focused in vitro experiments. 
Finally, we designed a Mg/PLGA barrier membrane, Mg micromesh and Mg tenting screw 
and combined them into a new approach to dental bone grafting. We used these new devices to 
refine a new surgical model for our research group and hypothesized that the devices could be 
successfully implanted in a vertical ridge augmentation model and support bone regeneration. We 
showed that all devices could be manufactured and successfully implanted; however, further work 
is needed to develop a more reliable surgical model. The vertical ridge augmentation model will 
likely prove useful in the future for combination with in vitro mechanistic studies as discussed 
above. Elucidation of the dynamics of hydrogen gas evolution and gas exchange surrounding these 
magnesium implants is also greatly needed. As observed in the vertical ridge augmentation model, 
this buildup of gas may inhibit osseointegration and bone regeneration and may even cause bone 
resorption. 
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Overall, this work advanced the field of magnesium in terms of novel material 
development, medical device development and biological understanding. As more magnesium 
devices move towards the clinic, deeper understanding of biocompatibility issues surrounding 
various magnesium device compositions and applications will be required to ensure patient safety. 
Additionally, this deeper understanding can be harnessed to optimize device design to provide a 
wound or defect environment most suitable for tissue regeneration. 
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